59 Discovery of novel inhibitor of FOXO nuclear-cytoplasmic shuttling from natural products of marine origin (Unknown)
- New search for: Correa, F.J.C.
- New search for: de Pedro, N.
- New search for: Quesada, L.R.
- New search for: Costales, D.O.
- New search for: Tormo, J.R.
- New search for: Martin, J.
- New search for: Reyes, F.
- New search for: Genilloud, O.
- New search for: Vicente, F.
- New search for: Correa, F.J.C.
- New search for: de Pedro, N.
- New search for: Quesada, L.R.
- New search for: Costales, D.O.
- New search for: Tormo, J.R.
- New search for: Martin, J.
- New search for: Reyes, F.
- New search for: Genilloud, O.
- New search for: Vicente, F.
In:
EUROPEAN JOURNAL OF CANCER -A-
;
50
;
24
;
2014
-
ISSN:
- Article (Journal) / Print
-
Title:59 Discovery of novel inhibitor of FOXO nuclear-cytoplasmic shuttling from natural products of marine origin
-
Contributors:Correa, F.J.C. ( author ) / de Pedro, N. ( author ) / Quesada, L.R. ( author ) / Costales, D.O. ( author ) / Tormo, J.R. ( author ) / Martin, J. ( author ) / Reyes, F. ( author ) / Genilloud, O. ( author ) / Vicente, F. ( author )
-
Published in:EUROPEAN JOURNAL OF CANCER -A- ; 50 ; 24
-
Publisher:
- New search for: Elsevier Science B.V., Amsterdam
-
Publication date:2014-01-01
-
Size:24 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:Unknown
- New search for: 616.994
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.994 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 50
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1.e1
-
EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectumvan de Velde, C.J.H. / Boelens, P.G. / Borras, J.M. / Coebergh, J.-W. / Cervantes, A. / Blomqvist, L. / Beets-Tan, R.G.H. / van den Broek, C.B.M. / Brown, G. / Van Cutsem, E. et al. | 2014
- 3
-
1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trialsMeric-Bernstam, F. / Brusco, L. / Kopetz, S. / Davies, M. / Routbort, M.J. / Piha-Paul, S.A. / Alvarez, R. / Khose, S. / De Groot, J. et al. | 2014
- 7
-
3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancerBlagden, S. / Hamilton, A. / Mileshkin, L. / Hall, M. / Meniawy, T. / Wong, S. / Anandra, S. / Buck, M. / McAleer, D. et al. | 2014
- 7
-
2 Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumorsPatnaik, A. / LoRusso, P. / Munster, P. / Tolcher, A.W. / Davis, S.L. / Heymach, J. / Ferraroto, R. / Xu, L. / Kapoun, A.M. et al. | 2014
- 8
-
4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2Taplin, M.E. / Chi, K.N. / Chu, F. / Cochran, J. / Edenfield, W.J. / Antonarakis, E.S. / Emmenegger, U. / Heath, E.I. / Hussain, A. et al. | 2014
- 8
-
6 Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sectionsMansfield, J.R. / Slater, C. / Wang, C. / Roman, K. / Hoyt, C.C. / Byers, R.J. et al. | 2014
- 8
-
5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinibSrinivasan, R. / Su, D. / Stamatakis, L. / Siddiqui, M.M. / Singer, E. / Shuch, B. / Nix, J. / Friend, J. / Hawks, G. et al. | 2014
- 9
-
8 Imaging growth and anti-cancer activity in orthotopic patient derived tumorsBaugher, M. / Bull, C. / Cohen-Barnhouse, A. / Flecha, A. / Franklin, M. / Guley, K. / McConville, P. / Leopold, W.R. et al. | 2014
- 9
-
7 Mouse clinical trial - A new preclinical study concept using patient-derived xenograftsVuaroqueaux, V. / Gredy, C. / Gorynia, S. / Baltes, S. / Fiebig, H.H. / Metz, T. et al. | 2014
- 9
-
9 Antineoplastic effects of auranofin in canine lymphomaThamm, D. / Rose, B.J. / Shoeneman, J.K. et al. | 2014
- 10
-
12 Next generation sequencing (NGS) guided therapy prediction for the treatment of glioblastoma multiforme (GBM)Sarkaria, J. / Ma, D.M. / Peng, S.P. / Byron, S.B. / Craig, D.C. / Carpten, J.C. / Berens, M.B. / O'Neill, B.O. / Tran, N.T. et al. | 2014
- 10
-
10 mTOR inhibition with everolimus - a novel treatment option for head and neck cancer identified in a translational research study using patient-derived xenograftsKlinghammer, K. / Raguse, J.D. / Plath, T. / Albers, A.E. / Brzezicha, B. / Wulf-Goldenberg, A. / Keilholz, U. / Hoffmann, J. / Fichtner, I. et al. | 2014
- 10
-
11 A panel of patient derived xenograft models of different haematological malignancies suitable for preclinical drug screening campaignsOswald, E. / Tschuch, C. / Klingner, K. / Hammerich, B. / Lehnhard, D. / Rentsch, C. / Lubbert, M. / Fiebig, H.H. / Schuler, J. et al. | 2014
- 11
-
13 Whole exome sequence analysis of canine transitional cell carcinoma of the bladderDuval, D.L. / Hernandez, B. / Brown, J. / Lana, S.E. / Page, R. / Jones, K.L. et al. | 2014
- 11
-
15 Genetic and molecular validation of uterine sarcoma patient-derived xenograft modelsCuppens, T. / Hermans, E. / Depreeuw, J. / Moisse, M. / Van Brussel, T. / Coenegrachts, L. / Lambrechts, D. / Amant, F. et al. | 2014
- 11
-
16 Allografting improves the feasibility of genetically engineered mouse models (GEMM) for anti-cancer drug developmentKukuk, K. / Klingner, K. / Peille, A.L. / Muller, P. / Zipelius, A. / Schuler, J. et al. | 2014
- 11
-
14 Mixeno mouse models for in vivo evaluation of anti-human cancer immunotherapeuticsZhang, J. / Qiu, J. / Qiao, M. / Shi, Q. et al. | 2014
- 12
-
17 Studies on glycoprotein expression differences between MCF-7 and MCF-7-ZNer-Kluza, J. / Drabik, A. / Kubbutat, M. / Lingnau, A. / Silberring, J. et al. | 2014
- 12
-
20 miR-25 is a key regulator of prostate cancer invasiveness by modulation of the cross-talk between Notch and TGF-@b signalingZoni, E. / van de Merbel, A.F. / van der Horst, G. / Rane, J. / Visakorpi, T. / Snaar, E.B. / Maitland, N. / van der Pluijm, G. et al. | 2014
- 12
-
19 Syngeneic models for developing cancer therapeutics targeting immune systemZhang, L. / Zhang, J. / Shi, Q. et al. | 2014
- 12
-
18 Establishment and characterization of a Merkel Cell carcinoma PDX panel: Screening for potentially useful therapiesWick, M.J. / Meade, J. / Nehls, M. / Vaught, T. / Carlile, J. / Tolcher, A.W. / Rasco, D.W. / Patnaik, A. / Papadopoulos, K.P. et al. | 2014
- 13
-
21 Pharmacogenomics of mithramycin in thoracic malignanciesFigg, W. / Sissung, T.M. / Peer, C.J. / Schrump, D. et al. | 2014
- 13
-
23 Phase I study of lurbinectedin (PM01183) administered on days (D) 1 & 8 every 3 weeks (q3wk) in patients (pts) with solid tumorsRatain, M.J. / Gore, L. / Szyldergemajn, S. / Diamond, J. / Geary, D. / Fernandez-Teruel, C. / Soto-Matos, A. / Sharma, M. / Jimeno, A. et al. | 2014
- 13
-
22 Novel combination therapy, TAS-102 combined with the anti-EGFR antibody or the anti-VEGF antibody showed therapeutic benefit toward colorectal cancer xenograftsIshida, K. / Sakamoto, K. / Tanaka, N. / Oguchi, K. / Yamamura, K. / Fujioka, A. / Nakagawa, F. / Matsuo, K. / Utsugi, T. et al. | 2014
- 14
-
25 An ING1b-derived peptide that inhibits cancer cell viability and promotes apoptosisBoyko, A. / Riabowol, K. et al. | 2014
- 14
-
26 NPD926, a small molecule inducer of reactive oxygen species, kills cancer cells via glutathione depletionKawamura, T. / Kondoh, Y. / Muroi, M. / Kawatani, M. / Osada, H. et al. | 2014
- 14
-
24 Androgen receptor (AR) expression in triple negative breast cancer (TNBC): results from a phase II neoadjuvant trial with carboplatin and eribulin mesylate in TNBC patientsSiziopikou, K. / Parini, V. / Kaklamani, V. et al. | 2014
- 15
-
28 Characterization of the type of cell death induced by novel tambjamine analogs in lung cancerMartin, A.R. / Soto-Cerrato, V. / Manuel-Manresa, P. / Korrodi-Gregorio, L. / Quesada, R. / Perez-Tomas, R. et al. | 2014
- 15
-
29 TAS-114 is a novel dUTPaseDPD inhibitor, its DPD inhibition reduces capecitabine dosage but does not diminish therapeutic window in human tumor xenograftsYano, W. / Kazuno, H. / Yokogawa, T. / Sakamoto, K. / Yoshisue, K. / Wakasa, T. / Fukuoka, M. / Matsuo, K. / Noguchi, K. et al. | 2014
- 15
-
27 TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancerOguchi, K. / Sakamoto, K. / Kazuno, H. / Ueno, H. / Ishida, K. / Yokogawa, T. / Yamamura, K. / Kitamura, R. / Matsuo, K. et al. | 2014
- 16
-
32 Replication stress is a determinant of synergy between gemcitabine and Chk1 inhibitionKoh, S.B. / Courtin, A. / Boyce, R. / Boyle, B. / Richards, F.M. / Jodrell, D.I. et al. | 2014
- 16
-
31 N-Myc amplification sensitizes tumor cells to inhibition by Danusertib, an Aurora kinase inhibitorCarpinelli, P. / Ceruti, R. / Alzani, R. / Re, C. / Ballinari, D. / Cribioli, S. / Russo, M. / Degrassi, A. / Texido, G. et al. | 2014
- 16
-
33 Combining the long-acting topoisomerase 1-inhibitor etirinotecan pegol with the PARP inhibitor rucaparib to provide anti-tumor synergy without increased toxicityHoch, U. / Charych, D. et al. | 2014
- 16
-
30 The fungal-derived cyclohexadepsipeptide Destruxin E exerts multifaceted anticancer and antiangiogenic activitiesDornetshuber-Fleiss, R. / Heffeter, P. / Mohr, T. / Hazemi, P. / Kryeziu, K. / Seger, C. / Berger, W. / Lemmens-Gruber, R. et al. | 2014
- 17
-
34 Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphomaLin, C. / Su, W. / Lee, J. / Hsu, C. / Cheng, A. / Ho, H. / Huang, C. / Hsueh, S. et al. | 2014
- 17
-
36 Suppression of metastasis and improvement of drug distribution by eribulin mesylateOzawa, Y. / Okamoto, K. / Adachi, Y. / Asano, M. / Tabata, K. / Funahashi, Y. / Matsui, J. et al. | 2014
- 17
-
37 Effect of a microtubule-targeting drug on cell-cell contacts in bladder epithelial tumour cellsAnton-Aparicio, L.M. / Castosa, R. / Haz, M. / Blanco, M. / Rodriguez, M. / Valladares, M. / Figueroa, A. et al. | 2014
- 17
-
35 BRCA1 expression exploratory analysis in patients of the phase III trial of trabectedin vs. doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomasAracil, M. / Lardelli, P. / Nieto, A. / Galmarini, C.M. et al. | 2014
- 18
-
39 Phytochemical indole-3-carbinol synergizes strongly with fludarabine and induces p53-dependent and -independent cell death in chronic lymphocytic leukemia cells irrespective of their IGHV mutation state and treatment resistancesPerez-Chacon, G. / Martinez-Laperche, C. / Rebolleda, N. / Somovilla-Crespo, B. / Munoz-Calleja, C. / Buno, I. / Zapata, J.M. et al. | 2014
- 18
-
40 Selectivity and mechanism of action studies for Polo Box-targeted, non-ATP based inhibitors of PLK1Baxter, M. / Craig, S. / McInnes, C. / Wyatt, M.D. et al. | 2014
- 18
-
38 The indolyl-chalcone CDD-026 induces cancer cell death through targeting of STMN1 and mitotic catastropheWegiel, B. / Wang, Y. / Jernigan, F. / Sun, L. et al. | 2014
- 19
-
41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage IIIIV non-small cell lung cancerNatale, R. / Socinski, M. / Hart, L. / Lipatov, O. / Spigel, D. / Gershenhorn, B. / Weiss, G. / Kazmi, S. / Karaseva, N. et al. | 2014
- 19
-
43 CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitorsHung, L. / Chen, Y. / Lin, H. / Tsai, M. / Hsieh, H. / Chang, J. / Chen, N. / Yang, S. / Chen, T. et al. | 2014
- 19
-
42 Interaction of SJG-136 with cognate sequences of oncogenic transcription factorsMantaj, J. / Jackson, P.J. / Thurston, D.E. / Rahman, K.M. et al. | 2014
- 20
-
44 Metformin and its impact on gastric cancer patients survival after gastrectomyLee, C.K. / Jung, M.K. / Jung, I.K. / Heo, S.J. / An, J.Y. / Kim, H.I. / Chung, J.H. / Hyung, W.J. / Noh, S.H. et al. | 2014
- 20
-
46 Broad-spectrum preclinical combination activity of eribulin combined with various anticancer agents in human breast cancer, lung cancer, ovarian cancer, and melanoma xenograft modelsAsano, M. / Matsui, J. / Towle, M.J. / Wu, J. / McGonigle, S. / Uenaka, T. / Nomoto, K. / Littlefield, B.A. et al. | 2014
- 20
-
47 Lurbinectedin (PM01183) specifically targets RNA Pol II for degradation via the proteasome pathway in a transcription and TC-NER dependent fashionSantamaria, G. / Martinez-Leal, J.F. / Cuevas, C. / Garcia-Fernandez, L.F. / Galmarini, C.M. et al. | 2014
- 20
-
45 Early preclinical study of BO-2094 for treatment of human colon cancer, in combination with 5-fluorouracilSu, T.L. / Ou, T.H. / Wu, M.H. / Lin, Y.W. / Lee, T.C. et al. | 2014
- 21
-
49 siRNA targeting of mitochondrial thymidine kinase 2 (TK2) sensitizes cancer cells to gemcitabine and increases mitochondrial toxicityDi Cresce, C. / Ferguson, P. / Figueredo, R. / Rytelewski, M. / Vareki, S.M. / Vincent, M.D. / Koropatnick, J. et al. | 2014
- 21
-
50 The effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors or lymphomasZhou, X. / Nemunaitis, J. / Pant, S. / Bauer, T. / Lockhart, A. / Patel, M. / Zhang, B. / Kelly, V. / Ullmann, C.D. et al. | 2014
- 21
-
48 Trabectedin and lurbinectedin are effective against leukemic cells derived from patients affected by chronic and juvenile myelomonocytic leukemiaRomano, M. / Galli, A. / Panini, N. / Paracchini, L. / Beltrame, L. / Bello, E. / Licandro, S.A. / Cattrini, C. / Tancredi, R. et al. | 2014
- 22
-
53 Adeno-associated virus (AAV) carrying diphtheria toxin a gene for pancreatic cancer therapyChen, M. / Ho, C.Y. / Teng, M. / Chen, H. et al. | 2014
- 22
-
52 Platinum(IV) derivatives of oxaliplatin: Cellular effects and in vivo potencyGoschl, S. / Pichler, V. / Brynzak, E. / Heffeter, P. / Jungwirth, U. / Jakupec, M.A. / Berger, W. / Galanski, M. / Keppler, B.K. et al. | 2014
- 22
-
51 Development of rational combination therapy strategies to optimize treatment for GPNMB expressing Her2+ and triple negative breast cancerRose, A. / Maric, G. / Annis, M.G. / Smith, H. / Muller, W.J. / Siegel, P.M. et al. | 2014
- 23
-
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC"1"0"0) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)Delbaldo, C. / Serin, D. / Mousseau, M. / Greget, S. / Audhuy, B. / Priou, F. / Berdah, J. F. / Teissier, E. / Laplaige, P. / Zelek, L. et al. | 2014
- 23
-
56 Radiosensitizing effect of sodium metaarsenite in a metastatic brain tumor modelKang, W.Y. / Park, Y.M. / Kim, S.J. et al. | 2014
- 23
-
55 Low, frequent doses of PM060184 induce remarkable in vivo antitumor activityAviles, P. / Guillen, M.J. / Lopez-Casas, P.P. / Sarno, F. / Cataluna, O. / Nunez, P. / Cuevas, C. / Hidalgo, M. et al. | 2014
- 23
-
54 MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patientsBarault, L. / Amatu, A. / Bleeker, F.E. / Moutinho, C. / Cassingena, A. / Tosi, F. / Venesio, T. / Esteller, M. / Bardelli, A. et al. | 2014
- 24
-
57 Differential antitumor activity of trabectedin, lurbinectedin, Zalypsis and PM00128 against a panel of human cells deficient in transcription and NER factorsMoneo, V. / Avila, S. / Martinez, P. / de Castro, B. / Cascajares, S. / Cuevas, C. / Garcia-Fernandez, L.F. / Galmarini, C.M. et al. | 2014
- 24
-
58 Pipecolidepsin A, Stellatolide A and Irvalec: New cyclodepsipeptides of marine origin with antitumor activityMolina-Guijarro, J.M. / Moneo, V. / Martinez-Leal, J.F. / Cuevas, C. / Garcia-Fernandez, L.F. / Galmarini, C.M. et al. | 2014
- 24
-
59 Discovery of novel inhibitor of FOXO nuclear-cytoplasmic shuttling from natural products of marine originCorrea, F.J.C. / de Pedro, N. / Quesada, L.R. / Costales, D.O. / Tormo, J.R. / Martin, J. / Reyes, F. / Genilloud, O. / Vicente, F. et al. | 2014
- 24
-
60 Sodium metaarsenite cytotoxic activity is associated with telomere length and many types of arsenic transporters in non-small cell lung cancerPark, Y.M. / Kim, S.J. et al. | 2014
- 25
-
63 Radium-223 dichloride - Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasisSuominen, M.I. / Fagerlund, K.M. / Rissanen, J.P. / Konkol, Y. / Alhoniemi, E. / Mumberg, D. / Ziegelbauer, K. / Kaskonen, S.M. / Halleen, J.M. et al. | 2014
- 25
-
62 Antitumor and temozolomide-sensitizing effects of sodium metaarsenite in an orthotopic glioblastoma xenograft modelKang, W.Y. / Park, Y.M. / Kim, S.J. et al. | 2014
- 25
-
61 A panel of pediatric liver cancer patient-derived xenografts to improve stratification of children with hepatoblastomaFabre, M. / Nicolle, D. / Gorse, A. / Deas, O. / Mussini, C. / Brugieres, L. / Ghigna, M.R. / Fadel, E. / Galmiche-Rolland, L. et al. | 2014
- 26
-
65 Phase II drug metabolism UGT1A enzyme affects cellular response of colon cancer cells to antitumor triazoloacridinone C-1305 treatmentAugustin, E. / Bartusik, E. / Theus, A. / Borowa-Mazgaj, B. / Mazerska, Z. et al. | 2014
- 26
-
64 Nifuroxazide halogenic derivatives induce ROS-mediated apoptosis and display antitumor activity against metastatic melanomade Farias, C.F. / Massaoka, M.H. / Girola, N. / Figueiredo, C.R. / Azevedo, R.A. / Tavares, L.C. / Travassos, L.R. et al. | 2014
- 26
-
66 Clinical validity of new genetic biomarkers of irinotecan neutropenia: An independent replication studyInnocenti, F. / Ramirez, J. / Qiao, W. / de Graan, A.J. / Ratain, M.J. / van Schaik, R.H.N. / Mathijssen, R.H.J. / Rosner, G.L. / Crona, D.J. et al. | 2014
- 27
-
67 Cytotoxic response as a result of the cross-talk between UGT mediated metabolism and modulation of UGT activity by C-1311 and C-1305 acridinone antitumor agents in selected solid tumor cell linesMazerska, Z. / Pawlowska, M. / Bejrowska, A. / Szydlowska, M. / Fedejko, B. / Augustin, E. et al. | 2014
- 27
-
68 Can the P53 status predict the outcome of Polo-like kinase 1 inhibition in non-small cell lung cancer cell lines?Van den Bossche, J. / Wouters, A. / Deben, C. / Deschoolmeester, V. / Specenier, P. / Pauwels, P. / Peeters, M. / Lardon, F. et al. | 2014
- 27
-
69 AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancerSanz, F.C. / Montemurro, F. / Rossi, V. / Verma, C. / Berger, M. / Baselga, J. / Scaltriti, M. et al. | 2014
- 28
-
72 Nrf2 as a molecular target in overwhelming chemoresistance in breast cancer therapySamadi, N. / Ramezani, F. / Sabzichi, M. et al. | 2014
- 28
-
73 Differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancerSos, M. / Levin, R.S. / Gordan, J.D. / Oses-Prieto, J.A. / Webber, J.T. / Salt, M. / Hann, B. / Burlingame, A.L. / McCormick, F. et al. | 2014
- 28
-
70 Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRa-expressing cellsPan, J. / Shen, Y. / Ding, K. et al. | 2014
- 28
-
71 Novel regulation of estrogen receptor transcription by the PI3K pathwayToska, E. / Elkabets, M. / Bosch, A. / Litvin, O. / Scaltriti, M. / Baselga, J. et al. | 2014
- 29
-
76 Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitorsMarusiak, A.A. / Edwards, Z.C. / Hugo, W. / Trotter, E.W. / Girotti, M.R. / Stephenson, N.L. / Kong, X. / Gartside, M.G. / Fawdar, S. et al. | 2014
- 29
-
75 Loss of PTEN leads to acquired resistance to the PI3Ka inhibitor BYL719: a case of convergent evolution under selective therapeutic pressureCastel, P. / Juric, D. / Griffith, M. / Griffith, O.L. / Won, H.H. / Ainscough, B. / Ellis, H. / Ebbesen, S. / Gopakumar, I. et al. | 2014
- 29
-
74 Increased EDN1 expression mediates acquired resistance to the combination therapy of PI3K and MEK inhibitors for colorectal cancerBhattacharya, B. / Low, S.H.H. / Benoukraf, T. / Chong, M.L. / Koh, K.X. / Soong, R. et al. | 2014
- 30
-
79 Quantitative proteomics as a tool to identify resistance mechanisms in erlotinib-resistant subclones of the non-small cell lung cancer cell line HCC827Jacobsen, K. / Lund, R.R. / Beck, H.C. / Ditzel, H.J. et al. | 2014
- 30
-
78 A comprehensive in vitro screen to identify therapeutic candidates for inclusion with etoposideplatin combinations to improve treatment of SCLCEvans, D. / Delosh, R. / Laudeman, J. / Ogle, C. / Reinhart, R. / Selby, M. / Silvers, T. / Monks, A. / Polley, E. et al. | 2014
- 30
-
77 Tumor suppressive roles of miR-221 and miR-222 in lung cancerSato, M. / Yamashita, R. / Kakumu, T. / Hase, T. / Maruyama, E. / Sekido, Y. / Kondo, M. / Hasegawa, Y. et al. | 2014
- 31
-
82 Regorafenib resistance in colorectal carcinoma is associated with enhanced expression of type II interleukin 1 receptor and reversed by MEKERK inhibitorMar, A.C. / Chu, C.H. / Shiau, C.W. / Lee, T.C. et al. | 2014
- 31
-
81 Sensitization of triple-negative breast cancer to PI3K inhibition by cotargeting IGF1Rde Lint, K. / Poell, J.B. / Rodriguez, J.V. / Soueidan, H. / Nijkamp, W. / Wessels, L.F. / Beijersbergen, R.L. et al. | 2014
- 31
-
80 Determination of an oxidative stress gene signature in inflammatory breast cancer patient tumors and development of a novel redox modulatory strategy in overcoming chemotherapy resistance and mediating anti-tumor efficacyDevi, G.R. / Allensworth, J.L. / Evans, M. / Ueno, N. / McDonnell, D. / Bertucci, F. / Van Laere, S. et al. | 2014
- 31
-
Impact of the transition from screen-film to digital screening mammography on interval cancer characteristics and treatment - A population based study from the NetherlandsNederend, J. / Duijm, L. E. M. / Louwman, M. W. J. / Coebergh, J. W. / Roumen, R. M. H. / Lohle, P. N. / Roukema, J. A. / Rutten, M. J. C. M. / van Steenbergen, L. N. / Ernst, M. F. et al. | 2014
- 31
-
83 Acquired resistance to BET bromodomain inhibitors is associated with modulation of the apoptotic signaling networkSandy, P. / Nerle, S. / Conery, A. / Hatton, C. / Bryant, B. / Sims, R. / Normant, E. et al. | 2014
- 32
-
86 Influence of EGFR exon 19 mutation subtypes on survival outcomes in advanced stage Asian non-small cell lung cancer patients receiving TKI therapyChowbay, B. / Singh, O. / Sutiman, N. / Tan, D.S.W. / Lim, W.T. / Tan, E.H. et al. | 2014
- 32
-
84 Src family kinase activation is a compensatory survival mechanism for acquired resistance to EGFR-TKIs in lung cancer cellsOno, M. / Sonoda, K. / Azuma, K. / Watari, K. / Molina, M. / Rosell, R. / Kuwano, M. et al. | 2014
- 32
-
87 Critical difference in development of acquired resistance to MDM2 inhibitor SAR405838 in vitro and in vivoHoffman-Luca, G. / Yang, C.Y. / Lu, J. / Ziazadeh, D. / McEachern, D. / Debussche, L. / Wang, S. et al. | 2014
- 32
-
85 Wnt secretion is required to maintain Wnt activity in colon cancerVoloshanenko, O. / Erdmann, G. / Dubash, T.D. / Augustin, I. / Metzig, M. / Ball, C.R. / Glimm, H. / Spang, R. / Boutros, M. et al. | 2014
- 33
-
88 Genome-wide drug sensitivity screens in haploid mouse embryonic stem cellsPettitt, S.J. / Krastev, D. / Pemberton, H. / Fontebasso, Y. / Bajrami, I. / Kozarewa, I. / Frankum, J. / Rafiq, R. / Campbell, J. et al. | 2014
- 33
-
89 Tie-2 regulates the stemness of prostate cancer cellsTang, K. / Ling, M. et al. | 2014
- 33
-
90 Tumor infiltrating leukocyte subpopulations as a biomarker of response and resistance to targeted therapy in patients with BRAF mutation-positive metastatic melanomaKelley, M.C. / Doxie, D.B. / Greenplate, A.R. / Crandall, H. / Sosman, J.A. / Irish, J.M. et al. | 2014
- 34
-
92 Role of ERK nuclear translocation in cisplatin-sensitive and -resistant ovarian cancer cellsDilruba, S. / Kalayda, G.V. / Jaehde, U. et al. | 2014
- 34
-
93 A stress induced early innate response causes multi-drug tolerance in melanomaMenon, D.R. / Das, S. / Krepler, C. / Vultur, A. / Rinner, B. / Schauer, S. / Kashofer, K. / Wagner, K. / Zhang, G. et al. | 2014
- 34
-
91 4E-BP1 expression levels determine sensitivity of triple negative breast cancer cells to mTOR inhibitorsJastrzebski, K. / Thijssen, B. / Rodriguez, J.V. / de Lint, K. / Lieftink, C. / Wessels, L.F. / Beijersbergen, R.L. et al. | 2014
- 35
-
97 Utilization of low passage adenoid cystic carcinoma PDX models to identify novel combination therapiesWick, M.J. / Meade, J. / Vaught, T. / Nehls, M. / Flores, J. / Kaufman, J. / Tolcher, A.W. / Rasco, D.W. / Patnaik, A. et al. | 2014
- 35
-
94 Elucidating mechanisms of resistance to FGFR inhibitors in endometrial cancerPacker, L. / Byron, S. / Mahon, C. / Loch, D. / Wortmann, A. / Nones, K. / Grimmond, S. / Pearson, J. / Waddell, N. et al. | 2014
- 35
-
95 Identification of synthetic lethality compounds from natural products for cancersNg, K.W. / Lee, K.S. / Patel, V. / Sundaramoorthy, E. / Ayoub, N. / Su, X. / Venkitaraman, A. / Teo, S.H. et al. | 2014
- 35
-
96 Evaluation of hormone therapies in a panel of breast PDX models: Relevance of ER status on sensitivity to letrozole and tamoxifenWick, M.J. / Vaught, T. / Gamez, L. / Meade, J. / Diaz, A. / Papadopoulos, K.P. / Rasco, D.W. / Patnaik, A. / Beeram, M. et al. | 2014
- 36
-
101 PIK3CA mutation-targeting compounds analyses using NCI60 cell line panelBando, H. / Lih, J. / Polley, E.C. / Holbeck, S.L. / Das, B. / Sims, D. / Doi, T. / Ohtsu, A. / Williams, M. et al. | 2014
- 36
-
99 Combination screening of investigational oncology agentsHolbeck, S. / Collins, J.M. / Doroshow, J.D. et al. | 2014
- 36
-
98 Synergistic inhibition of HER2 positive breast cancer by triptolide and lapatinibChalugun, P. / Shim, J.S. / Korangath, P. / Sukumar, S. / Liu, J.O. et al. | 2014
- 36
-
100 Small molecules selectively targeting breast cancer cellsSakoff, J. / Gilbert, J. / McCluskey, A. et al. | 2014
- 37
-
104 Identification of inhibitors of tryptophan metabolizing enzymes for cancer immunotherapy by high-throughput screeningZaman, G. / Uitdehaag, J.C.M. / van Gerwen, S. / Seegers, N. / van Doornmalen, A.M. / de Man, J. / Buijsman, R.C. et al. | 2014
- 37
-
103 The use of next generation sequencing (NGS) in the management of metastatic breast cancer (MBC): Defining a model for genomic-driven therapiesAustin, L. / Gooptu, M. / Avery, T. / Jaslow, R. / Palazzo, J. / Cristofanilli, M. et al. | 2014
- 37
-
102 Comparison of platinumtaxane and anthracycline-based therapies in ovarian PDX models: Correlating stage of biopsy collection and engrafting with in vivo drug sensitivityMeade, J. / Wick, M.J. / Vaught, T. / Gamez, L. / Farley, M. / Moriarty, A. / Tolcher, A.W. / Patnaik, A. / Rasco, D.W. et al. | 2014
- 38
-
105 A platform to test multiple therapy options simultaneously in a patient's own tumorCaffo, N. / Klinghoffer, R. et al. | 2014
- 38
-
106 Beta-3 integrin inhibition reduces inflammatory cytokine release but not anti-cancer activity of oncolytic adenovirus in ovarian cancerBrowne, A.K. / Tookman, L.A. / Ingemarsdotter, C.K. / Bouwman, R. / Pirlo, K. / Wang, Y. / Hodivala-Dilke, K.M. / McNeish, I.A. / Lockley, M. et al. | 2014
- 38
-
107 CIGB-247: Anti-VEGF therapeutic vaccine in patients with advanced solid tumorsHernandez-Bernal, F. / Gavilondo, J.V. / Avila, M.A. / de la Torre, A.V. / de la Torre, J. / Selman-Housein, K.H. / Morera, Y. / Bequet-Romero, M. / Valenzuela, C.M. et al. | 2014
- 39
-
108 CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and hematological malignanciesJacobs, J. / Zwaenepoel, K. / Aftimos, P. / Rolfo, C. / Rottey, S. / de Lendonck, L.Y. / Silence, K. / Awada, A. / Thibault, A. et al. | 2014
- 39
-
109 Functional activity, but not PD-1 expression level, differentiates primary CLL from healthy PD1+ T cells using SCNPLiang, S. / Leung, L. / Putta, S. / Hotson, D. / Rosen, D. / Hawtin, R.E. et al. | 2014
- 39
-
110 IL-6STAT3Fra-1 signaling axis promotes colorectal cancer aggressiveness through epithelial-mesenchymal transitionShao, J. / Liu, H. et al. | 2014
- 39
-
111 Identification of peptides which could block PD-1 checkpoint for NSCLC immunotherapyZhu, Y. / Li, C. et al. | 2014
- 40
-
A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancerLange, A. / Prenzler, A. / Frank, M. / Kirstein, M. / Vogel, A. / von der Schulenburg, J.M. et al. | 2014
- 40
-
112 A novel primary human tumor explant platform provides a preclinical translational link from tissue culture to the clinicJuan, G. / Paweletz, K. / Trueblood, E. / Rossi, J. / Damore, M. / Anderson, A. / Loberg, R. et al. | 2014
- 40
-
113 Preclinical activity and pharmacodynamic biomarkers of W014A, a PD-1 decoy peptide blocking both PD-1 immune checkpoint ligands, PD-L1 and PD-L2Bailly, C. / Broussas, M. / Ramachandra, M. / Sasikumar, P.G. / Shrimali, K. / Adurthi, S. / Satyam, L.K. / Dhudashia, A.A. et al. | 2014
- 40
-
114 Toll-like receptor 5 agonist entolimod as a potential anticancer immunotherapeutic agentBurdelya, L. / Brackett, C. / Kojouharov, B. / Veith, J. / Gudkov, A. et al. | 2014
- 40
-
115 Anti-metastatic activity via co-blockade of PD-1 and adenosine A2A receptorMittal, D. / Young, A. / Stannard, K. / Teng, M.W. / Allard, B. / Stagg, J. / Smyth, M.J. et al. | 2014
- 41
-
116 Novel targets for antibody-drug conjugate therapyGrandi, A.G. / Campagnoli, S.C. / Parri, M.P. / de Camilli, E.D.C. / Jin, B.J. / Sarmientos, P.S. / Grandi, G.G. / Terracciano, L.T. / Pileri, P.P. et al. | 2014
- 41
-
118 Major synergy between Coxsackievirus A21 (CAVATAK(TM)) and radiotherapy or chemotherapy in bladder cancerSimpson, G.R. / Annels, N. / Ajaz, M. / Launchbury, F. / Bolton, G. / Melcher, A.A. / Harrington, K.J. / Au, G. / Shafren, D. et al. | 2014
- 41
-
117 ''Arming'' the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumoursChampion, B. / Kodialbail, P. / Illingworth, S. / Rasiah, N. / Cochrane, D. / Beadle, J. / Fisher, K. / Brown, A.C.N. et al. | 2014
- 42
-
120 Density of CD 8 +ve T cells & CD 56 +ve NK cells in follicular adenoma & papillary carcinoma of thyroid in Pakistani populationVarda, J. / Naseem, N. / Nagi, A.H. et al. | 2014
- 42
-
121 A modified double-deleted vaccinia virus combining viral oncolysis and potential gene therapy as a novel therapeutic for atypical teratoidrhabdoid tumorsRuan, Y. / Narendran, A. et al. | 2014
- 42
-
119 3-Bromopyruvate as an inducer of immunogenic cell death in colon cancer cellsJung, K.H. / Lee, J.H. / Park, J.W. / Quach, C. / Lee, K.H. et al. | 2014
- 43
-
122 Analysis of immune-response markers in resectable NSCLCUso, M. / Jantus-Lewintre, E. / Sirera, R. / Calabuig-Farinas, S. / Gallach, S. / Escorihuela, E. / Blasco, A. / Guijarro, R. / Camps, C. et al. | 2014
- 43
-
124 A WT1-derived peptide protects against metastatic melanoma in a syngeneic model by in vivo immunomodulatory effects on dendritic cellsMassaoka, M.H. / Figueiredo, C.R. / Girola, N. / Azevedo, R.A. / Travassos, L.R. et al. | 2014
- 43
-
123 Targeting tryptophan metabolism in human lung cancerDeshane, J. / Schafer, C. / Wang, Y. / Sawant, A. / Jin, T.H. / Zhi, D. / Ponnazhagan, S. / Grant, S. et al. | 2014
- 44
-
126 IMCgp100: A novel bi-specific biologic for the treatment of malignant melanomaShingler, W. / Harper, J. / Bossi, G. / Barker, D. / Dukes, J. / Liddy, N. / Paston, S. / Mahon, T. / Molloy, P. et al. | 2014
- 44
-
127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in >=50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation populationGaron, E.G. / Rizvi, N.A. / Leighl, N.B. / Hui, R. / Eder, J.P. / Patnaik, A. / Aggarwal, C. / Horn, L. / Balmanoukian, A.S. et al. | 2014
- 44
-
125 Critical issues in the clinical development of oncolytic viruses - A regulatory perspectiveSchuessler-Lenz, M. et al. | 2014
- 45
-
130 Preclinical results of ProCervix, a first in class, first in indication therapeutic vaccine targeting HPV1618 infected womenEsquerre, M. / Bouillette-Marussig, M. / Goubier, A. / Momot, M. / Keller, H. / Bissery, M. et al. | 2014
- 45
-
128 T cell-mediated cancer immunotherapy through OX40 agonismHuseni, M. / Du, C. / Zhu, J. / Pacheco-Sanchez, P. / Moskalenko, M. / Chiu, H. / Dalpozzo, K. / Totpal, K. / Damico-Beyer, L. et al. | 2014
- 45
-
129 Characterization of PD-L1 expression in circulating tumor cells (CTCs) of non-small cell lung cancer (NSCLC) patientsKrupa, R. / Lu, D. / Harvey, M. / Louw, J. / Jendrisak, A. / Marrinucci, D. / Dittamore, R. et al. | 2014
- 46
-
133 Analysis of immune microenvironment in resectable NSCLC: Prognostic value of regulatory and conventional T cell markers proportionUso, M. / Sirera, R. / Calabuig-Farinas, S. / Blasco, A. / Pastor, E. / Guijarro, R. / Jantus-Lewintre, E. / Forteza, J. / Camps, C. et al. | 2014
- 46
-
131 Zfra activates novel Hyal2+ CD3- CD19- memory spleen cells to block cancer growth, stemness, and metastasis in vivoChang, N. et al. | 2014
- 46
-
132 A novel anti-PDL1 antibody-based bifunctional protein with enhanced immunological activityWu, Y. / Martomo, S. / Zhong, Z. / Lu, D. / Polonskaya, Z. / Luna, X. / Zhang, Z. / Zhang, H. / Witte, L. et al. | 2014
- 47
-
135 AD-O64.3: IFN-@c-TRAIL fusion protein. Use of two independent signaling pathways for a strong synergistic antitumor effectZerek, B. / Pieczykolan, J.S. / Pawlak, S.D. / Rozga, P.K. / Pieczykolan, A. / Szymanik, M. / Jaworski, A. / Galazka, M. / Bukato, K. et al. | 2014
- 47
-
136 Tumor-infiltrating lymphocytes (TILs) following intratumoral administration of ONCOS-102 are associated with prolonged overall survival in last line solid tumor patientsPesonen, S. / Joensuu, T. / Jager, E. / Karbach, J. / Wahle, C. / Kairemo, K. / Partanen, K. / Turkki, R. / Hemminki, A. et al. | 2014
- 47
-
134 Epigenetic immunomodulation by SGI-110 combined with immune checkpoint blockade for new therapeutic strategiesCovre, A. / Fazio, C. / Nicolay, H.J.M.G. / Natali, P.G. / Taverna, P. / Azab, M. / Coral, S. / Maio, M. et al. | 2014
- 48
-
139 GBR1302: a BEAT(R) bispecific antibody for the treatment of HER2 positive cancersCroset, A. / Macoin, J. / Ollier, R. / Pluess, M. / Delon, C. / Skegro, D. / Blein, S. / Hou, S. / Back, J. et al. | 2014
- 48
-
140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)Daud, A. / Hamid, O. / Robert, C. / Hodi, F.S. / Wolchok, J.D. / Hwu, W.J. / Weber, J.S. / Kefford, R. / Hersey, P. et al. | 2014
- 48
-
137 Immune checkpoint blockade enhances measles virotherapyEngeland, C.E. / Veinalde, R. / Grossardt, C. / Bossow, S. / Shevchenko, I. / Umansky, V. / Nettelbeck, D.M. / Jager, D. / von Kalle, C. et al. | 2014
- 48
-
138 Preclinical activity and safety of MGD006, a CD123xCD3 Bispecific DART(R) molecule for the treatment of hematological malignanciesMoore, P. / Chichili, G.R. / Huang, L. / Li, H. / Burke, S. / Chen, F. / He, L. / Tang, Q. / Jin, L. et al. | 2014
- 49
-
141 Phase I study of ipilimumab with stereotactic radiosurgery for melanoma patients with brain metastasesShi, W. / Wuthrick, E. / Feeney, K. / Werner-Wasik, M. / Andrews, D.W. / Evans, J.J. / Judy, K. / Farrell, C. / Dicker, A.P. et al. | 2014
- 49
-
142 IL-17 as a novel molecular target for prostate cancer preventionde Angulo, A. / Faris, R. / Jolly, C. / de Graffenried, L. et al. | 2014
- 49
-
143 Regional bias of intratumoral genetic heterogeneity of nucleotide repeats in colon cancers with microsatellite instabilityAn, C. / Choi, Y. / Kim, M. / Lee, J. / Yoo, N. / Lee, S. et al. | 2014
- 50
-
147 An integrated approach for identifying E-cadherin synthetic lethality networksBajrami, I. / Pettitt, S.J. / Brough, R. / Pemberton, H. / Kastrev, D. / Fontebasso, Y. / Frankum, J. / Campbell, J. / Ashworth, A. et al. | 2014
- 50
-
Population-based incidence, treatment and survival of patients with peritoneal metastases of unknown originThomassen, I. / Verhoeven, R.H.A. / van Gestel, Y.R.B.M. / van de Wouw, A.J. / Lemmens, V.E.P.P. / de Hingh, I.H.J.T. et al. | 2014
- 50
-
144 Association between interleukin 17interleukin 17 receptor gene polymorphism and papillary thyroid cancerEun, Y. / Chung, H. / Lee, Y.C. et al. | 2014
- 50
-
146 Establishment of patient-derived xenografts (PDX) models for triple negative breast cancer (TNBC) as a pre-clinical platform for drug developmentThatte, J. / Meza, M. / Ricono, J. / Broudy, T. / Mirsaidi, C. / Nair, P. et al. | 2014
- 50
-
145 ARQ 087, a novel pan FGFR-inhibitor crosses the BBB (blood-brain barrier) and distributes to the brain of ratsSavage, R. / Hall, T. / Schwartz, B. et al. | 2014
- 51
-
150 Pirin downregulates E-cadherin gene expression and contributes to EMTKomai, K. / Niwa, Y. / Sasazawa, Y. / Simizu, S. et al. | 2014
- 51
-
148 RAS synthetic lethal interactions from yeast to human cellsvan Wageningen, S. / Prahallad, A. / Heynen, G. / Rothstein, R. / Bernards, R. et al. | 2014
- 51
-
149 Quantitative mutational assessment of circulating tumor DNA using massively parallel deep sequencing in plasma and urine from advanced colorectal cancer patientsPoole, J.C. / Vibat, C.R.T. / Benesova, L. / Belsanova, B. / Hancock, S. / Lu, T.L. / Erlander, M.G. / Minarik, M. et al. | 2014
- 51
-
151 Impact of EGFR amplification pattern on the expression of miRNA-200c in primary glioblastoma multiformeHidalgo, L.M. / Gines, C.L. / Serna, E. / Monleon, D. / Callaghan, R. / Benso, R.G. / Martinetto, H. / Romero, A.G. / Darder, J.G. et al. | 2014
- 52
-
154 Drug response database with PDX tumor models in biomarker-driven multi-drug multi-arm clinical trial settingsJiang, J. / Yu, T.F. / Yan, Y. / Du, W. / Tan, T.T. / Hua, L. / Gu, J.L. / Yang, X.Q. / Liu, Z.H. et al. | 2014
- 52
-
152 Preclinical characterization of MM-151, an oligoclonal antibody therapeutic that targets EGFR by three distinct mechanisms of actionKing, A. / Sevecka, M. / Gerami-Moayed, N. / Burenkova, O. / Kearns, J. / Tan, G. / Sloss, C. / Bukhalid, R. / Nielsen, U. et al. | 2014
- 52
-
153 Moving beyond in vitro models and addressing the challenges of pooled RNAi screens in mouse xenograftsTedesco, D. / Bonneau, K. / Makhanov, M. / Deng, D. / Sun, P. / Chenchik, A. et al. | 2014
- 52
-
155 SNIPER(TACC3) degrades TACC3 protein via the ubiquitin-proteasome pathway and induces apoptosis in cancer cells expressing a large amount of TACC3Ohoka, N. / Nagai, K. / Okuhira, K. / Shibata, N. / Hattori, T. / Cho, N. / Naito, M. et al. | 2014
- 53
-
156 Behaviour of platinum(IV) complexes with prodrug function in different models of hypoxiaBrynzak, E. / Heffeter, P. / Pichler, V. / Jakupec, M.A. / Keppler, B.K. et al. | 2014
- 53
-
158 The development of a series of orthotopic solid tumour models of prostate, lung and ovarian cancer using optical and X ray imagingBatey, M. / Brown, M. / Bowden, E. et al. | 2014
- 53
-
159 Neoadjuvant chemotherapy in breast cancer patients induces expression of miR-34a and miR-122Freres, P. / Josse, C. / Bovy, N. / Boukerroucha, M. / Struman, I. / Bours, V. / Jerusalem, G. et al. | 2014
- 53
-
157 Sensitive and specific detection of 1p19q codeletion in gliomas by next generation sequencingDubbink, E. / Atmodimedjo, P.N. / van Marion, R.M. / Kros, J.M. / van den Bent, M.J. / Dinjens, W.N.M. et al. | 2014
- 54
-
160 Identification of fusion genes through kinome-centered RNA sequencing in different types of solid tumorsMittempergher, L. / Sun, C. / Groenendijk, F.H. / Bosma, A.J. / Willems, S.M. / Sustic, T. / Majewski, I.J. / Grernrum, W. / Davidson, N.M. et al. | 2014
- 54
-
161 Leveraging a novel DNA barcoding platform for integrated profiling and pharmacodynamic readoutsCastro, C. / Peterson, V. / Ullal, A. / Agasti, S. / Tuang, S. / Miller, N. / Birrer, M. / Weissleder, R. et al. | 2014
- 54
-
162 Drug-drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical dataBalani, S.K. / Bulychev, A. / Cohen, L. / Liao, M. / Xia, C.Q. / Wang, F. / Li, P. / LeClair, B. / Bohnert, T. et al. | 2014
- 55
-
165 Effect of zoledronic acid on the post-translational modification of activated leukocyte cell adhesion molecule (ALCAM) in cancer cellsToth, R. / Trombino, G. / Castronovo, V. / Bellahcene, A. et al. | 2014
- 55
-
166 Pre-clinical and clinical activity of Anti-DLL4 (demcizumab) in combination with gemcitabine plus nab-paclitaxel in pancreatic cancerHidalgo, M. / Cubillo, A. / Stagg, R. / Dupont, J. / Wan-Ching, Y. / Hoey, T. et al. | 2014
- 55
-
163 Interrogation of pharmacogenes in cancer patients using targeted DNA sequencingInnocenti, F. / Gillis, N. / Parker, J. / Hayes, N. / Eberhard, D. / Richards, K. / Auman, J.T. / Seiser, E. et al. | 2014
- 55
-
164 Augmentation of NAD+ by NQO1 activation attenuates cisplatin-mediated hearing impairmentYang, S. / Oh, G.S. / Kwon, K.B. / Park, R.K. / Lee, S.Y. / Moon, S.R. / So, H.S. et al. | 2014
- 56
-
168 CDCP1 as a new marker of aggressiveness in triple-negative breast cancersCampiglio, M. / Turdo, F. / Bianchi, F. / Sasso, M. / de Cecco, L. / Casalini, P. / Gasparini, P. / Forte, L. / Agresti, R. et al. | 2014
- 56
-
167 Genomic characterisation of 1003 cancer cell-linesBignall, G. / Iorio, F. / Futreal, P.A. / Stratton, M.R. / Campbell, P. / McDermott, U. et al. | 2014
- 56
-
169 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla(TM))Janku, F. / Huang, H.J. / Claes, B. / Falchook, G.S. / Naing, A. / Piha-Paul, S. / Tsimberidou, A.M. / Zinner, R.G. / Karp, D.D. et al. | 2014
- 57
-
170 Novel, ultra-deep next-generation sequencing for BRAF mutation testing using small amount of cell-free DNA from plasma of patients with advanced cancersJanku, F. / Huang, H.J. / Ramzanali, N.M. / Cai, X. / Klausner, R. / Meric-Bernstam, F. / Fan, J.B. et al. | 2014
- 57
-
173 Ras-mediated activation of mitogen-activated protein kinase pathway unleashes basement membrane damaging activity of serine protease hepsinTervonen, T. / Pant, S. / Belitskin, D. / Englund, J. / Narhi, K. / Verschuren, E. / Kovanen, P. / Klefstrom, J. et al. | 2014
- 57
-
171 Antagonistic interaction between gemcitabine and erlotinib is influenced by EGR1 (early growth response 1) transcription factor expressionHose, C.D. / Zhao, Y. / Polley, E.C. / Fang, J. / Fer, N.D. / Rapisarda, A. / Teicher, B.A. / Simon, R.M. / Doroshow, J.D. et al. | 2014
- 57
-
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerLoupakis, F. / Cremolini, C. / Salvatore, L. / Masi, G. / Sensi, E. / Schirripa, M. / Michelucci, A. / Pfanner, E. / Brunetti, I. / Lupi, C. et al. | 2014
- 57
-
172 Modulation of estrogen-dependent transcription by cohesin in MCF7 human breast adenocarcinoma cellsDasgupta, T. / Antony, J. / Rhodes, J. / McEwan, M. / Eccles, M. / Horsfield, J. et al. | 2014
- 58
-
174 Combination of molecular and drug response data in patient-derived xenografts to assist patient stratificationCairo, S. / Deas, O. / Beurdeley, A. / Yvonnet, V. / Poupon, M.F. / Judde, J.G. et al. | 2014
- 58
-
176 Resolvin D2 has mitogenic activity in estrogen receptor positive breast cancer cell lines via activation of estrogen receptorAl-Zaubai, N. / Johnstone, C. / Rizzacasa, M. / Stewart, A. et al. | 2014
- 58
-
175 Functional analysis of [methyl-^3H]choline uptake in glioblastoma cells: Influence of anti-cancer and central nervous system drugsInazu, M. / Taguchi, C. / Yamanaka, T. / Uchino, H. et al. | 2014
- 59
-
178 Establishment of patient-derived xenografts (PDX) models for small cell lung (SCL) as a pre-clinical platform for drug developmentBroudy, T. / Ricono, J. / Mullins, C. / Mirsaidi, C. / Nair, P. et al. | 2014
- 59
-
179 Effects of human breast cancer cells secreted factors on macrophage differentiationde Sousa, S.C. / Brion, R. / Monkkonen, J. / Joensuu, H. / Heymann, D. / Maatta, J. et al. | 2014
- 59
-
180 Identifying and monitoring somatic mutations in cell free DNA of patients with metastatic melanomaWisell, J. / Amato, C.M. / Robinson, W.A. et al. | 2014
- 59
-
177 Validation of 3D primary organoid cultures of colorectal carcinoma as discovery and validation platform for personalized cancer therapyHalonen, P. / Kuijpers, A. / Morris, B. / Diosdado, B. / Mainardi, S. / Bernards, R. / Verwaal, V. / Beijersbergen, R. et al. | 2014
- 60
-
184 Molecular profiling of heterogeneous tumor cellsChenchik, A. / Deng, D. / Bonneau, K. / Makhanov, M. / Coram, M. / Dolganov, G. / Jeffrey, S.S. et al. | 2014
- 60
-
181 Aberrant Wnt signaling activation in human cancers: In vitro and in vivo models to facilitate Wnt targeted drug developmentLiu, G. / Dong, C. / Zhang, R. / Zhang, L. / Qian, S. / Cai, J. / Zhang, J. / Ning, J. et al. | 2014
- 60
-
183 Spatio-temporal characterization of tumor growth and invasionJimenez, A.M. / Yogurtcu, O. / Horn-Lee, M. / Rao, P. / Sun, S.X. / Wirtz, D. et al. | 2014
- 60
-
185 Treatment of patient-derived NSCLC xenograft preclinical models using image-guided small animal irradiationPapadopoulou, N. / McKenzie, A. / King, J. / Page, M. / Kumari, R. et al. | 2014
- 60
-
182 TRAP1 represents a key mediator of stemness and glycolytic metabolism in colorectal cancer cellsLettini, G. / Maddalena, F. / Sisinni, L. / Condelli, V. / Del Vecchio, L. / Gemei, M. / Notarangelo, T. / Landriscina, M. et al. | 2014
- 61
-
186 The use of Quantitative Textural Analysis imaging biomarkers to predict response to temsirolimus treatment in advanced HCC subjectsKorn, R. / Osarogiagbon, R. / Newbold, R. / Burkett, D. / Sachdev, J. et al. | 2014
- 61
-
187 Targeted genomic profiling of penile squamous cell carcinoma using the Oncomine cancer research panelMcDaniel, A.S. / Hovelson, D. / Cani, A. / Liu, C.J. / Zhang, Y. / Sadis, S. / Bandla, S. / Williams, P. / Rhodes, D. et al. | 2014
- 61
-
188 RANBP2 knock-down is synthetic lethal with BRAF V600E in colon cancerVecchione, L. / Gambino, V. / d'Ario, G. / Tian, S. / Schlicker, A. / Mainardi, S. / Diosdado, B. / Simon, I. / Delorenzi, M. et al. | 2014
- 62
-
189 Molecular and pharmacological characterization of primary mesothelioma tumor cell lines orthotopically xenografted in nude micePisano, C. / Cole, A. / Barbarino, A. / Bianchino, E. / Guglielmi, M. / Melito, C. / Mercadante, G. / Porciello, A. / Riccio, A. et al. | 2014
- 62
-
192 Extensive characterization of patient derived colon cancer xenografts for preclinical biomarker identificationVuaroqueaux, V. / Kiefer, F. / Bronsert, P. / Peille, A.L. / Zeitouni, B. / Foucault, F. / Kees, T. / Guo, J. / Schuler, J. et al. | 2014
- 62
-
190 Differential chemosensitivity between CETCs and tumour spheroids in cancer patients with solid tumorsZimon, D. / Pizon, M. / Stein, E.L. / Pachmann, U. / Pachmann, K. et al. | 2014
- 62
-
191 Homotypic and heterotypic cell signaling transduction using a dielectrophoresis microfluidic deviceGabriel, M.T. / Heymann, D. et al. | 2014
- 63
-
195 A humanized mouse model for preclinical testing of molecules targeting immune checkpointsBaia, G. / Vasquez, D. / Ciznadija, D. / Sidransky, D. / Katz, A. / Paz, K. et al. | 2014
- 63
-
194 Pancreatic ductal organoids as a new platform for drug discoveryPonz-Sarvise, M. / Corbo, V. / Ohlund, D. / Oni, T. / Handly-Santana, A. / Engle, D. / Tiriac, H. / Chio, C. / Feigin, M. et al. | 2014
- 63
-
193 The identification of new therapies for ependymoma subgroupsBoulos, N. / Dapper, J.D. / Patel, Y.T. / DeCuypere, M. / Bianski, B. / Mohankumar, K.M. / Jacus, M.O. / III, B.F. / Wright, K.D. et al. | 2014
- 64
-
Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinomaJeon, H.G. / Choo, S.H. / Sung, H.H. / Jeong, B.C. / Seo, S.I. / Jeon, S.S. / Choi, H.-Y. / Lee, H.M. et al. | 2014
- 64
-
196 Neuropilin 2 (NRP2) modifies CXCL12CXCR4 signaling and promotes lymph node metastases in colon cancerSchneider, H. / Honscheid, P. / Scholch, S. / Jakob, C. / Muders, M. et al. | 2014
- 64
-
198 Genetic and pharmacological inhibition of PIM-1 reduces tumor development in a K-Ras-driven mouse model of non-small cell lung cancerAguirre, E. / Renner, O. / de Miguel, M.C.R. / Albarran, M.I. / Cebria, A. / Cebrian, D. / Ramos-Lima, F. / Pastor, J. / Blanco-Aparicio, C. et al. | 2014
- 64
-
197 Statistical aspects of kinetic analysis of gliomas with FDG-PETHawe, D. / Hernandez, F.R. / Murphy, S. / Wolsztynski, E. / Huang, J. / O'Sullivan, J. / Muzi, M. / Eary, J. / Krohn, K. et al. | 2014
- 65
-
201 Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancerKim, S. / Park, S.H. / Lee, J. / Park, Y.S. / Kim, H.C. et al. | 2014
- 65
-
199 Inhibitor of differentiation 1 (Id1) expression in lung cancer cells and liver microenvironment is required for liver metastasis (LM) development from non-small cell lung cancer (NSCLC) by regulating EMT-related and proliferation-related proteinsCastanon, E. / Soltermann, A. / Lopez, I. / Ecay, M. / Collantes, M. / Picazo, J.M.L. / Ponz, M. / Rolfo, C. / Calvo, A. et al. | 2014
- 65
-
202 The novel microtubule-destabilizing drug BAL101553 (prodrug of BAL27862) sensitizes a treatment refractory tumor model to ionizing radiationBroggini-Tenzer, A. / Bachmann, F. / Vuong, V. / Messikommer, A. / Nytko-Karouzakis, K. / O'Reilly, T. / Lane, H.A. / Pruschy, M.N. et al. | 2014
- 65
-
200 The influence of different cMET and EGFR backgrounds on the cytotoxicity of cMET and EGFR small molecule inhibitors in vitrovan der Steen, N. / Zwaenepoel, K. / Rolfo, C. / Giovannetti, E. / Castiglia, M. / Deschoolmeester, V. / Carreca, A.P. / Germonpre, P. / Pauwels, P. et al. | 2014
- 66
-
204 High-throughput functional screening identifies the flavoreductase POR as a principal determinant of sensitivity to the hypoxia-targeting prodrug SN30000Hunter, F.W. / Shalev, Z. / Wang, J. / Moffat, J. / Katella, T. / Koritzinsky, M. / Wilson, W.R. / Wouters, B.G. et al. | 2014
- 66
-
203 Ionizing radiation induced phosphatidylserine externalization on endothelial cell surface - a potential target for vascular targetingZhao, Z. / Johnson, M. / Chen, B. / Grace, M. / Ukath, J. / Lee, V. / Stoodley, M. et al. | 2014
- 67
-
206 Identification of novel targets for radiosensitisation of non-small cell lung cancer by secretome analysisSharma, A. / Bender, S. / Riesterer, O. / Broggini-Tenzer, A. / Pruschy, M. et al. | 2014
- 67
-
207 The enhancement of radiotherapy efficacy with docetaxel-titanate nanotubes as a new nanohybrid for localized high risk prostate cancerMirjolet, C. / Boudon, J. / Loiseau, A. / Chevrier, S. / Gautier, T. / Boidot, R. / Paris, J. / Millot, N. / Crehange, G. et al. | 2014
- 67
-
205 Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancerTroncone, M.J. / Cargnelli, S.M. / Pond, G. / Tsiani, E. / Wright, J. / Steinberg, G. / Skinner, H. / Bo, L. / Bradley, J. et al. | 2014
- 68
-
208 Combined treatment of a DNA-PKcs inhibitor (NU7441) and ionizing radiation causes a differential mode of cell death in a panel of NSCLC cell lines and exhibits robust radiosensitisationSaha, D. / Lan, Y. / Hsu, F. / Tumati, V. / Zhang, Z. / Lin, Y. / Chen, B. et al. | 2014
- 70
-
Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a Phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trialAitchison, M. / Bray, C.A. / Van Poppel, H. / Sylvester, R. / Graham, J. / Innes, C. / McMahon, L. / Vasey, P.A. et al. | 2014
- 71
-
209 Pre-clinical and translational pharmacology, pharmacokinetics and pharmacodynamics for a humanized anti-OX40 antibody MOXR0916, a T-cell agonist in the treatment of solid tumorsSukumaran, S. / Kim, J.M. / Huseni, M. / Ruppel, J. / Taylor, H. / Totpal, K. / Zhu, J. / Zhang, C. / Chiu, H. et al. | 2014
- 71
-
211 A novel synthetic lethal interaction between the histone mark H3K36me3 and checkpoint kinasesPfister, S.X. / Markkanen, E. / Jiang, Y. / Sarkar, S. / D'Angiolella, V. / Dianov, G. / Ryan, A.J. / Humphrey, T.C. et al. | 2014
- 71
-
210 A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancersLoRusso, P. / LaVallee, T. / Kimmel, L. / Lubeski, C. / Gedrich, R. / Sidor, C. et al. | 2014
- 72
-
213 A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumorsDoi, T. / Lin, C.C. / Ohtsu, A. / Yang, J.C.H. / Shitara, K. / Pronk, L.C. / Sarashina, A. / Cheng, A.L. et al. | 2014
- 72
-
214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancerHaluska, P. / Timms, K.M. / AlHilli, M. / Wang, Y. / Hartman, A.M. / Jones, J. / Gutin, A. / Sangale, Z. / Neff, C. et al. | 2014
- 72
-
212 Novel anti-tumor activity of targeted LSD1 inhibition by GSK2879552Mohammad, H. / Smitheman, K. / van Aller, G. / Cusan, M. / Kamat, S. / Liu, Y. / Johnson, N. / Hann, C. / Armstrong, S. et al. | 2014
- 73
-
216 Phase I study of panobinostat and fractionated stereotactic re-irradiation therapy (FSRT) for recurrent high grade gliomasShi, W. / Lawrence, Y.R. / Werner-Wasik, M. / Andrews, D.W. / Evans, J.J. / Glass, J. / Kim, L. / Ad, V.B. / Moshel, Y. et al. | 2014
- 73
-
215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparibSwisher, E. / Brenton, J. / Kaufmann, S. / Oza, A. / Coleman, R.L. / O'Malley, D. / Konecny, G. / Ma, L. / Harrell, M. et al. | 2014
- 73
-
217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advancedmetastatic hepatocellular carcinomaKang, Y.K. / Ryoo, B.Y. / Kim, T.Y. / Lee, K.H. / Lim, H.Y. / Lee, S.J. / Ikeda, M. / Okusaka, T. / Nadano, S. et al. | 2014
- 74
-
218 Genomic analysis identifies novel drivers and targetable pathways in inflammatory breast cancer patient samplesMoran, D.M. / Rao, K. / Bacon-Trusk, P. / Pry, K. / Weigman, V. / Velculescu, V. / Cristofanilli, M. / Bacus, S. et al. | 2014
- 74
-
219 Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients: A novel approach to treat HPV related malignancies?Deutsch, E. / Levy, A. / Mazeron, R. / Gazzah, A. / Angevin, E.A. / Ribrag, V. / Balheda, R. / Varga, A. / Lhomme, C. et al. | 2014
- 74
-
220 Overcoming drug-resistance in multiple myeloma by XPO1 inhibitor combination therapyTurner, J. / Dawson, J. / Grant, S. / Shain, K. / Cubitt, C. / Dai, Y. / Zhoui, L. / Kauffman, M. / Shacham, S. et al. | 2014
- 75
-
221 Docosahexaenoic acid along with modulation of actin binding proteins reduces cancer cell migrationAli, M. / Rogers, L.K. et al. | 2014
- 75
-
222 Estimating predictive values of short-term morphologic assays of cancer chemoprevention for efficacy in animal tumor assaysDunn, B. / Steele, V.E. / Fagerstrom, R.M. / Topp, C.F. / Ransohoff, D. / Cunningham, C. / Lubet, R. / Ford, L.G. / Kramer, B.S. et al. | 2014
- 75
-
223 Preclinical assessment of nintedanib for chemoprevention in hepatocellular carcinomaTovar, V. / Moeini, A. / Torrecilla, S. / Higuera, M. / Peix, J. / Quetglas, I.M. / Rodriguez-Carunchio, L. / Cornella, H. / Sole, M. et al. | 2014
- 76
-
225 Molecular targets of interest to the NCI PREVENT cancer preclinical drug development programShoemaker, R.H. / Dunn, B.K. / Suen, C. / Lubet, R.A. / Boring, D.L. / Klein, B.D. / Miller, M.S. / Steele, V.E. et al. | 2014
- 76
-
226 Efficacy of cancer preventing drugs administered by intermittent dosing regimensSteele, V.E. / Grubbs, C. / Rao, C.V. / Lubet, R.A. et al. | 2014
- 76
-
227 Multiplexed ICE COLD-PCR: A mutation detection methodology for achieving sensitivities of <0.01% using either Sanger or NGSWu, G. / Legendre, B. / Cherubin, S. / Cubrich, C. / Dowers, A. / Jensen, S. / Gniffke, J. / Kruempel, A. / Krzycki, P. et al. | 2014
- 76
-
224 Synergic tumor growth suppression with carbohydrate-restriction diet and natural AMP-dependent protein kinase activatorsChoi, M. / Lee, J. et al. | 2014
- 77
-
228 Her2-3 heterodimer is a new and better than HER2 IHC score for clinical outcome prognosisWeitsman, G. / Barber, P.R. / Lawler, K. / Gillett, C. / Woodman, N. / Kholodenko, B. / Nguyen, L.K. / Santra, T. / Vojnovic, B. et al. | 2014
- 77
-
230 High correlation between clinical responses to first line AML patients treated with cytarabine and idarubicin and their pharmacological profiles in patient samples measured by ExviTechBallesteros, J. / Hernandez, P. / Primo, D. / Robles, A. / Espinosa, A.B. / Arroyo, E. / Garcia-Navas, V. / Sanchez-Fenoy, J. / Jimenez, M. et al. | 2014
- 77
-
229 DNA methyltransferase 1 expression in human solid tumors and lymphomas by immunohistochemistryYang, S.X. / Nguyen, D. / Rubinstein, L. / Kummar, S. / Tomaszewski, J.E. / Doroshow, J.H. et al. | 2014
- 78
-
231 Clinical pharmacodynamic assay development for the first in class investigational ubiquitin activating enzyme (UAE) inhibitor MLN7243Bahamon, B. / Gao, F. / Stringer, B. / Yang, Y. / Shi, J. / Burke, K. / Huck, J. / Traore, T. / Bowman, D. et al. | 2014
- 78
-
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abirateroneBianchini, D. / Lorente, D. / Rodriguez-Vida, A. / Omlin, A. / Pezaro, C. / Ferraldeschi, R. / Zivi, A. / Attard, G. / Chowdhury, S. / de Bono, J. S. et al. | 2014
- 78
-
232 Development of a targeted NGS assay system for patient enrollment to the NCI-MATCH studyWilliams, M. / Sims, D. / Lih, J. / Datta, A. / Hamilton, S. / Iafrate, A.J. / Sklar, J. / Sadis, S. / Takabe, N. et al. | 2014
- 78
-
233 Analytical validation and application of the MPACT assay, a next generation sequencing based targeted mutation detection assay for treatment selectionLih, C. / Sims, D.J. / Harrington, R.D. / Polley, E.C. / Zhao, Y. / Simon, R.M. / Mehaffey, M.G. / Forbes, T.D. / Walsh, W.D. et al. | 2014
- 79
-
234 Kinetic analysis of dynamic ^1^1C-verapamil PET study: Compartmental v adaptive mixture models comparisonHernandez, F. / Hawe, D. / Murphy, S. / O'Sullivan, J. / Wolsztynski, E. / Huang, J. / Muzi, M. / Eary, J. / Krohn, K. et al. | 2014
- 79
-
235 Kinetic analysis of dynamic ^1^1C thymidine PET imaging studies: Compartmental and nonparametric approachesMurphy, S. / Hawe, D. / Hernandez, F. / Wolsztynski, E. / Huang, J. / O'Sullivan, J. / Muzi, M. / Eary, J. / Krohn, K. et al. | 2014
- 79
-
236 Whole genomic assay on endoscopic ultrasound-guided fine needle aspiration samples of unresectable pancreatic cancerHa, J.M. / Lee, K.H. / Lee, J.K. / Lee, K.T. / Park, W.Y. / Bae, J.S. / Jung, J.K. / Park, D.H. / Seong, Y.K. et al. | 2014
- 79
-
237 Impact of phase 1 expansion cohorts on probability of success in phase 2 and time-to-drug-approval: analysis of 385 new drugs in oncologyBugano, D. / Hess, K. / Siu, L.L. / Meric-Bernstam, F. / Razak, A.R.A. / Hong, D.S. et al. | 2014
- 80
-
239 Niraparib, a selective PARP 12 inhibitor, is efficacious in pre-clinical models of small-cell lung cancerWang, Y. / Ricono, J. / Admunson, K. / Agarwal, S. / Fram, R.J. / Broudy, T. / Wilcoxen, K.M. et al. | 2014
- 80
-
238 Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs)Johnson, S. / Johnson, N. / Chi, D. / Primack, B. / Cruz, C. / Stover, D. / Greifenberg, A.K. / Cao, S. / O'Connor, K. et al. | 2014
- 81
-
240 The combination of Chk-1 and ATR inhibitor synergistically kills cancer cellsSanjiv, K. / Hagenkort, A. / Reaper, P.M. / Koolmeister, T. / Mortusewicz, O. / Schultz, N. / Scobie, M. / Berglund, U.W. / Charlton, P.A. et al. | 2014
- 81
-
242 BMN 673 as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer modelsFeng, Y. / Post, L.E. / Cardnell, R. / Byers, L.A. / Wang, B. / Shen, Y. et al. | 2014
- 81
-
243 Modulation of PI3KmTOR pathway following PARP inhibition in small cell lung cancerCardnell, R.J. / Feng, Y. / Diao, L. / Fan, Y. / Masrorpour, F. / Mukherjee, S. / Shen, J. / Wang, J. / Byers, L.A. et al. | 2014
- 81
-
241 Epigenetic loss-of-function BRCA1 mediates tumor cure by single dose radiotherapyCampagne, C. / Thin, T.H. / Fuller, J.D. / Manova-Todorova, K. / Haimovitz-Friedman, A. / Powell, S.N. / Kolesnick, R.N. / Fuks, Z. et al. | 2014
- 82
-
244 Development of xenoimplants from germline BRCA12 mutant breast cancer (BC) for the identification of predictive biomarkers, mechanisms of resistance against poly(ADP-ribose) polymerase (PARP) inhibitors and evaluation of novel therapiesCruz, C. / Ibrahim, Y. / Morancho, B. / Anton, P. / Grueso, J. / Cozar, P. / GuzmAn, M. / Aviles, P.M. / Guillen, M.J. et al. | 2014
- 82
-
246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanismHopkins, T. / Solomon, L. / Shi, Y. / Rodriguez, L. / Donawho, C. / DiGiammarino, E. / Panchal, S. / Olson, A. / Stolarik, D. et al. | 2014
- 82
-
245 Chk1 is a potential novel therapeutic target that regulates cell survival and potentiates chemotherapy in osteosarcoma (OS) modelsStrauss, S.J. / Mistry, P. / Mendoza, A. / Robson, M. / Holme, H. / Nandabhiwat, P. / Kwok, B. / Qadir, M. / Pedley, R.B. et al. | 2014
- 83
-
248 Use of ATR inhibitor in combination with topoisomerase I inhibitor kills cancer cells by disabling DNA replication initiation and fork elongationJosse, R. / Martin, S.E. / Guha, R. / Ormanoglu, P. / Pfister, T. / Morris, J. / Doroshow, J. / Pommier, Y. et al. | 2014
- 83
-
249 Preclinical efficacy of the PARP inhibitor rucaparib (CO-338AG014699PF-01367338) in pancreatic cancer models with homologous recombination deficiencies (HRD)Robillard, L. / Lin, K. / Lopez-Casas, P.P. / Hidalgo, M. / Harding, T.C. et al. | 2014
- 83
-
247 Selective inhibitors of nuclear export (SINE) block the expression of DNA damage repair proteins and sensitize cancer cells to DNA damage therapeutic agentsKashyap, T. / Crochiere, M. / Friedlander, S. / Klebanov, B. / Senapedis, W. / Baloglu, E. / del Alamo, D. / Tamir, S. / Rashal, T. et al. | 2014
- 84
-
250 Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genesChmielecki, J. / Hutchinson, K.E. / Frampton, G.M. / Chalmers, Z.R. / Johnson, A. / Shi, C. / Elvin, J. / Ali, S.M. / Ross, J.S. et al. | 2014
- 84
-
253 Phase 1 correlative study of ARQ761, a @b-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosisGerber, D. / Arriaga, Y. / Beg, M.S. / Dowell, J.E. / Schiller, J.H. / Frankel, A.E. / Leff, R. / Meek, C. / Bolluyt, J. et al. | 2014
- 84
-
251 A combined in vitro and mathematical modelling approach for understanding the impact of an inhibitor of ATR on DNA damage and repair after ionising radiationYates, J. / Checkley, S. / MacCallum, L. / Odedra, R. / Barnes, J. / Lau, A. et al. | 2014
- 84
-
252 The DNA damage response gene Schlafen 11 (SLFN11) is a transcriptional target of ETS transcription factors in Ewing's sarcoma and other cancersPommier, Y. / Bilke, S.W. / Sousa, F. / Yamade, M. / Murai, J. / Rajapakse, V. / Helman, L. / Meltzer, P. et al. | 2014
- 85
-
Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract - A systematic review and meta-analysisThomas, L.K. / Bermejo, J.L. / Vinokurova, S. / Jensen, K. / Bierkens, M. / Steenbergen, R. / Bergmann, M. / von Knebel Doeberitz, M. / Reuschenbach, M. et al. | 2014
- 85
-
256 Minicell packaged targeted delivery of shRNA to cancer cellsJivrajani, M. / Shrivastava, N. / Nivsarkar, M. et al. | 2014
- 85
-
254 Molecular analysis in breast cancer: correlation with Immunohistochemical classification and pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC)Baulies, S. / Gonzalez-Cao, M. / Karachaliou, N. / Capitan, A.R. / Molina-Vila, M.A. / Cusido, M.T. / Teixido, C. / Viteri, S. / Fabregas, R. et al. | 2014
- 85
-
255 Pre-clinical in vivo characterization of MLN7243, an investigational ubiquitin activating enzyme inhibitor, in solid tumor modelsTraore, T. / Huck, J.H. / Shi, J.S. / Sappal, D.S. / Duffey, J.D. / Yang, Y.Y. / Kadakia, E.K. / Chakravarty, A.C. / Stringer, B.S. et al. | 2014
- 86
-
257 Development of peptide-mediated drug delivery systems for colon cancer targeted imaging and therapyWu, H.C. / Wu, C.H. / Kuo, Y.H. et al. | 2014
- 86
-
258 Pancreatic cancer cells expressing the OATP1B3 transporter show promising sensitivity to the highly cytotoxic microcystin-LR moleculeKounnis, V. / Chondrogiannis, G. / Mantzaris, M.D. / Fokas, D. / Papanikolaou, N.A. / Sainis, I. / Briasoulis, E. et al. | 2014
- 86
-
259 Factors that limit delivery of Cdk46 inhibitor palbociclib to GBMParrish, K. / Pokorny, J. / Mittapalli, R. / Bakken, K. / Sarkaria, J. / Elmquist, W. et al. | 2014
- 87
-
260 Hsp90 Inhibitor Drug Conjugates (HDC): Payloads and possibilitiesChimmanamada, D. / Ying, W. / Zhang, J. / Proia, D. / Przewloka, T. / Jiang, J. / Vutukuri, D. / Lu, G. / Osman, S. et al. | 2014
- 87
-
262 Improved cytotoxic activity of Nor-@b-lapachone-loaded PLGA microcapsules in PC3M prostate cancer cell linePessoa, C. / Feitosa, A.C.S. / Costa, M.P. / Evangelista, F.C. / Sales, F.A.M. / Bomfim, I.S. / Junior, E.N.S. / Dias, G.G. / Freire, V.N. et al. | 2014
- 87
-
263 Controlled release of cisplatin using hyaluronic oligosaccharides-coated gold nanoparticles as an efficient delivery system applied to the treatment of pancreatic tumorsParkkola, H. / Amieva, L.S. / Vivero, L. / Minana, R. / Sendra, J. et al. | 2014
- 87
-
261 Lesion characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation with treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)Ramanathan, R.K. / Korn, R.L. / Sachdev, J.C. / Fetterly, G.J. / Jameson, G. / Marceau, K. / Marsh, V. / Raghunand, N. / Prey, J. et al. | 2014
- 88
-
265 Pretargeted nanoparticles to deliver both chemotherapeutics and radiation for the treatment of lymphomaFang, C. / Jones, J.C. / Frayo, S.M. / Hylarides, M.H. / Zhang, M. / Press, O.W. et al. | 2014
- 88
-
264 Vasculogenic mimicry in small cell lung cancerTrapani, F. / Metcalf, R.L. / Polanski, R. / Fusi, A. / Hodgkinson, C. / Nonaka, D. / Hendrix, M.J. / Morrrow, C. / Blackhall, F. et al. | 2014
- 89
-
269 The NCI-60 as an effective tool for scaffold hopping: A phenotypic systems-based approach to the design of novel chemotherapeuticsWishka, D.G. / Kumar, V. / Teicher, B. / Kaur, G. / Fang, B. / Risbood, P. / Hollingshead, M. / Zais, J. / Morris, J. et al. | 2014
- 89
-
268 A potent and highly efficacious bivalent Smac Mimetic APG-1387 in Phase I clinical developmentLu, J. / Rong, S. / Sun, H. / Liu, L. / McEachern, D. / Wang, G. / Wen, J. / Zhai, Y. / Guo, M. et al. | 2014
- 89
-
266 Auxiliar treatment by targeting the extracellular matrix to improve drug delivery and therapeutic responseHenke, E. / Roehrig, F. / Hoffmann, H. / Escorcia, F. / Wartenberg, M. / Volova, S. / Gaetzner, S. / Rosenwald, A. / Erguen, S. et al. | 2014
- 89
-
267 Novel adjuvant therapy with leptin peptide receptor antagonist-2 conjugated to nanoparticles (IONP-LPrA2) to minimize chemoresistance in triple negative breast cancerHarmon, T. / Harbuzariu, A. / Yang, L. / Gonzalez-Perez, R.R. et al. | 2014
- 90
-
270 Discovery, development and optimization of low molecular weight EPH-ephrin protein-protein inhibitorsTognolini, M. / Giorgio, C. / Hassan-Mohamed, I. / Barocelli, E. / Mor, M. / Pala, D. / Russo, S. / Incerti, M. / Lodola, A. et al. | 2014
- 90
-
272 8-(1-Anilino)ethyl)-2-morpholino-4-oxo-4H-chromene-6-carboxamides as PI3Kbetadelta inhibitors: structure-activity relationships and identification of AZD8186, a clinical candidate for the treatment of PTEN deficient tumoursBarlaam, B. / Cosulich, S. / Degorce, S. / Fitzek, M. / Green, S. / Hancox, U. / Lambert-van der Brempt, C. / Lohmann, J.J. / Maudet, M. et al. | 2014
- 90
-
271 Data integration and graph analysis for cancer genomics and drug discoveryBernard, B. / Miller, M. / Rovira, H. / Shmulevich, I. et al. | 2014
- 91
-
273 Significance of serine-167 and cysteine-129 residues in the active site of the immune-suppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) for the binding of novel inhibitorsTomek, P. / Palmer, B.D. / Flanagan, J.U. / Ching, L. et al. | 2014
- 91
-
275 Modulation of PIP2 levels through small molecule inhibition of PIP5KAndrews, D. / Cosulich, S. / Divecha, N. / Fitzgerald, D. / Flemington, V. / Jones, C. / Jones, D. / Kern, O. / MacDonald, E. et al. | 2014
- 91
-
274 Novel cysteine derivatives for the next generation anticancer agents acting on KSPOgo, N. / Sawada, J. / Ishikawa, Y. / Matsuno, K. / Hashimoto, A. / Asai, A. et al. | 2014
- 91
-
276 An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinonesAnil, B. / Blackburn, E. / Blackburn, T. / Cully, S. / Liu, J. / Drummond, C.J. / Endicott, J.A. / Golding, B.T. / Griffin, R.J. et al. | 2014
- 92
-
277 The discovery and pre-clinical development of the first clinical stage EZH2-inhibitor, EPZ-6438 (E7438)Kuntz, K. / Keilhack, H. / Pollock, R. / Knutson, S. / Warholic, N. / Richon, V. / Chesworth, R. / Copeland, R. / Porter-Scott, M. et al. | 2014
- 92
-
279 Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agentHsieh, H.P. / Kuo, C.C. / Chiu, J.J. / Hsu, T.A. / Yeh, T.K. / Chen, C.T. et al. | 2014
- 92
-
278 Sentinel lymph nodes mapping of macrophage targeted mannosyl human serum albumin-indocyanine detected by combined color and near infrared fluorescence imaging system in esophagusQuan, Y. / Oh, Y. / Park, J.I.H.O. / Park, J. / Jeong, J. / Kim, B. / Kim, H. et al. | 2014
- 93
-
282 Membrane anchorage of Stat3 via artificial protein lipidationAvadisian, M. / Fletcher, S. / Liu, B. / Zhao, W. / Turkson, J. / Gradinaru, C. / Gunning, P. et al. | 2014
- 93
-
281 Novel hybrid drug design strategy to circumvent erlotinib resistance and to optimize its pharmacokinetic properties for treating lung cancerPoon, D.C.S. / Au-Yeung, S.C.F. / To, K.K.W. et al. | 2014
- 93
-
280 A hybrid drug design approach to overcome imatinib resistance for treating leukemiaWei, Y.M. / To, K.K.W. / Au-Yeung, S.C.F. et al. | 2014
- 94
-
284 Poly(ADP-ribose) glycohydrolase (PARG) inhibitors increase nuclear poly(ADP-ribose) after methylating DNA damageJordan, A. / Acton, B. / Fairweather, E. / Hamilton, N. / Holt, S. / Hitchin, J. / Hutton, C. / James, D. / Jones, S. et al. | 2014
- 94
-
283 The development of the first selective inhibitors of the UBA5 enzyme to probe for E1 activity in diseased cellsda Silva, S.R. / Paiva, S.L. / Bancerz, M. / Geletu, M. / Lewis, A.M. / Chen, J. / Cai, Y. / Li, H. / Gunning, P.T. et al. | 2014
- 94
-
285 A nanomolar-potency small molecule inhibitor of the STAT5 proteinCumaraswamy, A.A. / Lewis, A. / Geletu, M. / Todic, A. / Diaz, D.B. / Cheng, X.R. / Brown, C.E. / Laister, R. / Muench, D. et al. | 2014
- 95
-
287 The discovery and optimization of small molecule antagonists of the WDR5-MLL interactionAl-Awar, R. / Al-Awar, R.S. / Getlik, M. / Smil, D. / Bolshan, Y. / Poda, G. / Senisterra, G. / Wu, H. / Allali-Hassani, A. et al. | 2014
- 95
-
288 Synthetic isomalyngamide A analogs that inhibit breast cancer migrationLi, W. / Chang, T. / Hung, C. / Chen, C. / Jao, S. et al. | 2014
- 95
-
286 Potent and selective non-sulfamate-containing small molecule inhibitors of the ubiquitin activating enzymePaiva, S. / da Silva, S.R. / Bancerz, M. / Quereshi, H. / Xu, G.W. / Schimmer, A.D. / Gunning, P.T. et al. | 2014
- 95
-
289 Progress in drugging CYP1A1, 1B1 and CYP2W1 overexpressed in cancerPors, K. / Le Morvan, V. / Travica, S. / Shnyder, S.D. / Sutherland, M. / Sheldrake, H.M. / Searcey, M. / Johansson, I. / Mkrtchian, S. et al. | 2014
- 96
-
293 Inhibition of the cell cycle regulated Cdc7 kinase pathway is an efficacious therapeutic approach for hematologic malignancies and solid tumorsSantos, R. / Shum, D. / Carrillo, D. / Zhang, R. / Churchill, M. / Mukherjee, S. / Brentjens, R. / Radu, C. / Kelly, T.J. et al. | 2014
- 96
-
291 Aflibercept has anti-tumor activity in bevacizumab-escaping tumors of colorectal cancer: Molecular profiles and mechanismsDib, C. / Bagley, R.G. / Mankoo, P. / Pollard, J. / Watters, J. / Chiron, M. et al. | 2014
- 96
-
292 Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle rendering them chemosensitiveYano, S. / Zhang, Y. / Zhao, M. / Hiroshima, Y. / Miwa, S. / Uehara, F. / Kishimoto, H. / Tazawa, H. / Fujiwara, T. et al. | 2014
- 96
-
290 Exosome analysis in cancer patients: From the preclinical towards the clinical application: Trial designMertens, I. / Castiglia, M. / Carreca, A.P. / Baggertman, G. / Peeters, M. / Pauwels, P. / Rolfo, C. et al. | 2014
- 97
-
296 A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignanciesShimizu, T. / Aida, H. / Horobin, J. / Keegan, M. / Padval, M. / Poli, A. / Hashii, C. / Nakagawa, K. et al. | 2014
- 97
-
295 Combining forces: Study of the cytotoxic effect of the MDM2 inhibitor Nutlin-3 in combination with CDDP in non-small cell lung cancer cell linesDeben, C. / Rolfo, C. / Deschoolmeester, V. / Wouters, A. / Peeters, M. / Gil-Bazo, I. / Lardon, F. / Pauwels, P. et al. | 2014
- 97
-
294 Synthetic lethal screen identifies Aurora A as a selective target in HPV driven cervical cancerGabrielli, B. / Bokhari, F. / Ranall, M. / Stevenson, A. / Murell, M. / Kelly, M. / McKee, S. / Leggatt, G. / Gonda, T. et al. | 2014
- 98
-
300 Preclinical pharmacologic characterization of GSK2849330, a monoclonal AccretaMab(R) antibody with optimized ADCC and CDC activity directed against HER3Clarke, N. / Hopson, C. / Hahn, A. / Sully, K. / Germaschewski, F. / Yates, J. / Akinseye, C. / Mangatt, B. / Jonak, Z. et al. | 2014
- 98
-
298 Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expressionKim, C. / Lee, B.S. / Kim, K.A. / Song, Y.J. / Cheong, K.H. et al. | 2014
- 98
-
299 Tyk2-src dependence of kidney cancerKrishnan, B. / Hanna, S.C. / Wilson, H.L. / Bailey, S.T. / Damrauer, J.S. / Simamura, T. / Levine, R.L. / Wong, K.K. / Johnson, G.L. et al. | 2014
- 98
-
297 Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLCChen, J. / Amato, K. / Wang, S. / Youngblood, V. / Brantley-Sieders, D. / Cook, R. / Tan, L. / Gray, N. et al. | 2014
- 99
-
301 Using PKPDefficacy modeling to predict potential of AZD9291 to target brain metastases from advanced NSCLC with EGFR sensitizing mutations (EGFRm+)Yates, J. / Ballard, P. / Ashton, S. / Cross, D. / Dattani, R. / Mellor, M. / Wilson, J. / Yang, P. / Xie, L. et al. | 2014
- 99
-
303 Genomic and epigenomic analysis identify potential therapeutic targets in luminal B breast cancer molecular subtypeKlouche, L.A. / Belhadj, A. / Bendaoud, A. / Benyelles, M. / Ziane, I. / Chaffanet, M. / Birnbaum, D. et al. | 2014
- 99
-
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - A study of the OVCAD consortiumPils, D. / Bachmayr-Heyda, A. / Auer, K. / Svoboda, M. / Auner, V. / Hager, G. / Obermayr, E. / Reiner, A. / Reinthaller, A. / Speiser, P. et al. | 2014
- 99
-
302 FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells which are enriched by standard of care chemotherapyPachter, J. / Kolev, V.N. / Baas, P. / Weaver, D.T. / Xu, Q. et al. | 2014
- 100
-
307 Stromal delivery of long Pentraxin-3 impairs FGFFGFR-dependent tumor growth and metastasisGiacomini, A. / Di Salle, E. / Coltrini, D. / Rezzola, S. / Belleri, M. / Presta, M. / Ronca, R. et al. | 2014
- 100
-
305 Selinexor, a novel selective inhibitor of nuclear export, potentiates the antitumor activity of gemcitabine against pancreatic cancer by nuclear retention of p27Amit, M. / Kazim, S. / Kazim, H. / Shacham, S. / Kauffman, M. / Malafa, M.P. et al. | 2014
- 100
-
306 CC-115 inhibits DNA damage and repair pathways in vitroTsuji, T. / Sapinoso, L. / Sankar, S. / Mortensen, D.S. / Xu, S. et al. | 2014
- 100
-
304 PI3'-Kinase inhibition forestalls the development of drug resistance in BRAFV600EPTENNull melanomaDeuker, M. / Durban, V.M. / Phillips, W. / McMahon, M. et al. | 2014
- 101
-
308 Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathwayGameiro, S. / Ardiani, A. / Kwilas, A.R. / Donahue, R.N. / Hodge, J.W. et al. | 2014
- 101
-
311 IGF-1R inhibition induced activation of YesSFK acts as a by-pass resistance pathway in rhabdomyosarcomaWan, X. / Yeung, C. / Heske, C. / Mendoza, A. / Hlman, L.J. et al. | 2014
- 101
-
310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101Anderson, D. / Ciomei, M. / Banfi, P. / Cribioli, S. / Ardini, E. / Galvani, A. / Li, G. et al. | 2014
- 101
-
309 RNA sequencing and in silico analysis identifies an unannotated antisense long non-coding RNA involved in cancer progressionInoue, S. / Horie-Inoue, K. / Ikeda, K. et al. | 2014
- 102
-
314 Optimal sequencing schedules for combining BRAF inhibition with BCL-2 inhibitionSchalck, A. / Frederick, D.T. / Hammond, M.R. / Ferreiro-Neira, I. / Cooper, Z.A. / Cusack, J.C. / Lawrence, D.P. / Flaherty, K.T. / Wargo, J.A. et al. | 2014
- 102
-
312 The prognostic role of mesothelin expression and its association with KRAS mutation in advanced lung adenocarcinomaThomas, A. / Chen, Y. / Steinberg, S. / Luo, J. / Giaccone, G. / Pastan, I. / Miettinen, M. / Hassan, R. et al. | 2014
- 102
-
313 Development of a one-step isolation platform for exosomal RNA and circulating cell-free DNA from cancer plasma samplesEnderle, D. / Brinkmann, K. / Koestler, T. / Bentink, S. / Berking, C. / Skog, J. / Noerholm, M. et al. | 2014
- 103
-
317 IKK@b inhibition suppresses sphere formation and self-renewal of lung cancer initiating cellsCarneiro-Lobo, T. / Salviatto, A.C.P. / Baldwin, A.S. / Basseres, D.S. et al. | 2014
- 103
-
315 Biological characterization of TAS3681, a new type of androgen receptor antagonist with androgen receptor downregulating activityMinamiguchi, K. / Seki, M. / Aoyagi, H. / Mori, T. / Kajiwara, D. / Masuko, N. / Fujita, R. / Okajima, S. / Hayashi, Y. et al. | 2014
- 103
-
316 Potent, partial agonists at ERalpha as selective estrogen mimics for treatment of tamoxifen-resistant breast cancerThatcher, G. / Xiong, R. / Patel, H.K. / Zhao, J. / Liang, X. / Wang, Y. / Molloy, M.E. / Tonetti, D. et al. | 2014
- 103
-
318 Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC)Miller, R.E. / Bajrami, I. / Brough, R. / Konde, A. / Campbell, J. / Rafiq, R. / Ashworth, A. / Lord, C.J. et al. | 2014
- 104
-
321 Potent and selective inhibition of EZH2 by AU-2121 leads to significant tumor growth inhibition in mutant EZH2 dependent non-Hodgkin lymphomaAhmed, S. / Narayanan, K. / Gadakh, A. / Dodheri, S. / Surendranath, S. / Nathan, S. / Mukherjee, S. / Marappan, S. / Sushmita, R. et al. | 2014
- 104
-
319 Genomic profiling of uterine leiomyosarcomas reveal frequent alterations in Aktmammalian target of rapamycin (mTOR) pathway genes and other actionable genomic abnormalities linked to targeted therapiesElvin, J.A. / Chalmers, Z.R. / Chiemlicki, J. / Wang, K.A.I. / Palma, N. / Ali, S.M. / Huho, A. / Sheehan, C.E. / Miller, V.A. et al. | 2014
- 104
-
320 First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphomaSaleh, M. / Papadpoulos, K. / Arabnia, A. / Patnaik, A. / Stein, R.M. / Chai, F. / Lamar, M. / Savage, R. / Abbadessa, G. et al. | 2014
- 105
-
324 Clinical pharmacokinetics (PK), translational PKpharmacodynamics (PD), and exposure-adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibitorZhou, X. / Olszanski, A.J. / Middleton, M. / Gonzalez, R. / Bargfrede, M.J. / Kneissl, M. / Bozon, V. / Gangolli, E. / Venkatakrishnan, K. et al. | 2014
- 105
-
323 The development of short form of mimic microRNA for lung cancer therapyOhno, S. / Sudo, K. / Kuroda, M. et al. | 2014
- 105
-
322 Novel alternative splice variants as potential biomarkers and therapeutic targets in aggressive prostate cancer in men of African descentPatierno, S. / Freedman, J. / Wang, B. / Lee, N. / George, D. et al. | 2014
- 106
-
327 Combination of MDM2 antagonists with RAS pathway inhibitors in colorectal cancerHiggins, B. / Tovar, C. / Kolinsky, K. / Zhang, Y. / Middleton, S.A. / Nichols, G. / Packman, K. / Su, F. / Vassilev, L. et al. | 2014
- 106
-
328 Jagged1 expression and its relevance in metastatic progression of breast cancersBednarz-Knoll, N. / Efstathiou, A. / Gotzhein, F. / Wilkman, H. / Mueller, V. / Kang, Y. / Pantel, K. et al. | 2014
- 106
-
325 Identification and characterization of an irreversible inhibitor of CDK2Martin, M. / Anscombe, E. / Meschini, E. / Staunton, D. / Geitmann, M. / Danielson, U.H. / Wang, L.Z. / Vidal, R.M. / Reuillon, T. et al. | 2014
- 106
-
326 A novel non-ligand competing anti-EGFR antibody for cancer treatmentWang, X. / Rust, S. / Comer, F. / Muniz-Medina, V. / Du, Q. / Yuan, A. / Senthil, K. / Fleming, R. / Minter, R. et al. | 2014
- 107
-
330 Preclinical development of BIS-1602, first in class growth hormone releasing hormone antagonistMaxuitenko, Y.Y. / Block, N.L. / Schally, A.V. / Reich, S.J. / Goldstein, P. et al. | 2014
- 107
-
331 Biomarker discovery and validation for assessing the response to cMet inhibition and functional inactivationJung, S. / Selzer, S. / Lo@bner, C. / Kuhn, K. / Fiedler, U. / KlotzbUcher, A. / Zucht, H.D. / Koncarevic, S. / Prinz, T. et al. | 2014
- 107
-
329 A first-in-human study evaluating the safety and pharmacology of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumorsBeeram, M. / Lieu, C. / Harb, W. / Power, L. / Kearns, J. / Nering, R. / Moyo, V. / Wolf, B. / Adjei, A. et al. | 2014
- 108
-
332 Dual PI3K deltagamma inhibition by RP6530 accentuates bortezomib activity in multiple myeloma cell linesViswanadha, S. / Babu, G. / Veeraraghavan, S. / Vakkalanka, S. et al. | 2014
- 108
-
335 RICTOR amplification as a novel molecular target for the treatment of lung cancerCheng, H. / Piperdi, B. / Zou, Y. / Verma, A. / Liu, X. / Schwartz, E. / Zhu, C. / Montagna, C. / Halmos, B. et al. | 2014
- 108
-
334 Aplidin: first in class compound targeting EEF1A in tumor cellsLosada, A. / Martinez, J.F. / Moral, P. / Carrasco, L. / Gago, F. / Cuevas, C. / Garcia-Fernandez, L.F. / Galmarini, C.M. et al. | 2014
- 108
-
333 Short antisense oligonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in human hepatocarcinoma cellsRoos, M. / Civenni, G. / Lucic, M. / Pavlicek, D. / Pradere, U. / Towbin, H. / Catapano, C.V. / Hall, J. et al. | 2014
- 109
-
336 The effect of food on the pharmacokinetics of the investigational Aurora A kinase (AAK) inhibitor, alisertib (MLN8237), in patients (pts) with advanced solid tumors or lymphomasZhou, X. / Bauer, T.M. / Goel, S. / Sarantopoulos, J. / Zhang, B. / Kelly, V. / Mertz, J. / Venkatakrishnan, K. et al. | 2014
- 109
-
337 Sensitisation of HPV+ HNSCC to cytotoxic treatments by targeting the G2M checkpoint with AZ-1775 to improve survivalOsman, A. / Tanaka, N. / Patel, A. / Wang, J. / Fitzgerald, A. / Xie, T. / Zhao, M. / Jasser, S. / Gadhikar, M. et al. | 2014
- 109
-
338 BM-1252 (APG-1252): a potent dual specific Bcl-2Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicityBai, L. / Chen, J. / Liu, L. / McEachern, D. / Aguilar, A. / Zhou, H. / Yang, C.Y. / Wang, H. / Wen, J. et al. | 2014
- 110
-
341 Dinaciclib alters cell cycle dynamics and induces cell death in Soft Tissue SarcomasMargalef, N.M. / Rello-Varona, S. / Garcia-Monclus, S. / Fuentes-Guirado, M. / Tirado, O.M. / del Muro, X.G. et al. | 2014
- 110
-
340 Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer modelsGuffanti, F. / Chila, R. / Bello, E. / Ceriani, L. / Zangarini, M. / Zucchetti, M. / Saba, C. / Jacquet-Bescond, A. / Pierrat, M. et al. | 2014
- 110
-
339 NAMPT inhibition as strategy to impair tumor growthCerezo, A. / Jimenez, S. / Lospitao, E. / Bravo, N. / Campos-Olivas, R. / Aguilera, C. / Canamero, M. / Gilmour, R. / Geeganage, S. et al. | 2014
- 111
-
345 Interaction of plitidepsin with eEF1A in living tumor cellsGarcia, C. / Losada, A. / Molina-Guijarro, J.M. / Sacristan, M.A. / Martinez, J. / Galmarini, C.M. / Lillo, M.P. et al. | 2014
- 111
-
343 Salmonella typhimurium A1-R effectively targets experimental breast cancer brain metastasisZhang, Y. / Miwa, S. / Zhang, N. / Hoffman, R.M. / Zhao, M. et al. | 2014
- 111
-
The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patientsvan der Ploeg, A. P. T. / van Akkooi, A. C. J. / Haydu, L. E. / Scolyer, R. A. / Murali, R. / Verhoef, C. / Thompson, J. F. / Eggermont, A. M. M. et al. | 2014
- 111
-
344 Search for new blood biomarkers for response to antiangiogenic therapy in non-small cell lung cancer patientsRodriguez-Garzotto, A. / Agullo-Ortuno, M.T. / Ponce, S. / Diaz-Garcla, C.V. / Agudo-Lopez, A. / Perez, C. / Prieto-Garcia, E. / Cortes-Funes, H. / Iglesias, L. et al. | 2014
- 111
-
342 A phase 12 study evaluating the safety, pharmacokinetics and efficacy of ABT-414 in subjects with advanced solid tumors likely to over-express the epidermal growth factor receptor (EGFR)Tolcher, A. / Goss, G. / Gordon, M. / Gandhi, L. / Papadopoulos, K.P. / Rasco, D. / Pedersen, M. / Fischer, J. / Ames, W. et al. | 2014
- 112
-
346 Inhibition of Wnt pathway by novel thiazole-based Traf2- and Nck-interacting kinase (TNIK) inhibitorUno, Y. / Moriyama, H. / Kashimoto, S. / Masuda, M. / Sawa, M. / Yamada, T. et al. | 2014
- 112
-
347 Can a link between the EGFR and cMET pathway in non-small cell lung cancer explain resistance against targeted therapies and open new therapeutic opportunities?van der Steen, N. / van der Steen, K. / Zwaenepoel, K. / Giovannetti, E. / Castiglia, M. / Carreca, A.P. / Pauwels, P. / Rolfo, C. et al. | 2014
- 112
-
348 Two NSCLC-PDXs with different EGFR exon 20-insertions respond differently to different TKIsLi, H. / Yang, M. / Cai, J. et al. | 2014
- 113
-
349 Synergistic drug combinations that target beta-catenin-driven and MYC-driven cancersUitdehaag, J.C.M. / Spijkers-Hagelstein, J.A.P. / de Roos, J.A.D.M. / van Doornmalen, A.M. / Prinsen, M.B.W. / de Man, J. / Buijsman, R.C. / Zaman, G.J.R. et al. | 2014
- 113
-
350 Oncogenic Ras mutants differentially utilize PLC-dependent calcium flux and PKC activation for MAPK signalingPitt, C. / McCormick, F. et al. | 2014
- 113
-
351 hz515H7, a humanized antibody exerts its antitumor activity via antagonism of the CXCR4SDF-1 axis, and through effector functionsKlinguer-Hamour, C. / Broussas, M. / Akla, B. / Berger, S. / Boute, N. / Beau-Larvor, C. / Robert, A. / Haeuw, J.F. / Goetsch, L. et al. | 2014
- 114
-
353 Protein expression for receptor activator of NFkB (RANK) and its ligand (RANKL) in non-small cell lung cancer (NSCLC)D'Arcangelo, M. / Ekman, S. / Dougall, W. / Branstetter, D. / Bergqvist, M. / Liv, P. / Chan, D. / Botling, J. / Hirsch, F. et al. | 2014
- 114
-
354 PCR-based assay for BRAFV600 mutation analysis in ctDNA: clinical results from plasma and serum samplesGonzalez-Cao, M. / de las Casas, C.M. / Molina-Vila, M.A. / de Mattos-Arruda, L. / Manzano, J.L. / Munoz, E. / Cortes, J. / Berros, J.P. / Sanmamed, M. et al. | 2014
- 114
-
352 UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute leukemiaGraham, D. / DeRyckere, D. / Wang, X. / Hill, A.A. / Zhang, W. / Frye, S.V. / Earp, H.S. et al. | 2014
- 115
-
355 Altiratinib (DCC-2701): a balanced inhibitor of MET, TIE2, and VEGFR2 kinases that exhibits broad anti-tumor and anti-angiogenic activitiesFlynn, D. / Smith, B.D. / Leary, C.B. / Kaufman, M.D. / Turner, B.A. / Hood, M.M. / Lu, W.P. / Rutkoski, T.J. / Samarakoon, T. et al. | 2014
- 115
-
358 Knockdown of beta-catenin with dicer-substrate siRNAs down-regulates Wntbeta-catenin pathway signalingPursell, N. / Zhou, W. / Diwanji, R. / Holmes, B. / Avitahl-Curtis, N. / Dutta, C. / Dudek, H. / Ganesh, S. / Abrams, M. et al. | 2014
- 115
-
356 Discovery of novel pyrido[2,3-b]pyrazine as fibroblast growth factor receptor (FGFR-1, 2, 3 & 4) kinase inhibitors with nanomolar affinityAngibaud, P. / Querolle, O. / Berdini, V. / Saxty, G. / Cleasby, A. / Colombel, H. / Csoka, I. / Gilissen, R. / King, P. et al. | 2014
- 115
-
357 Multi-color flow cytometry immunophenotyping for detection of CSC in NSCLCMartinez-Romero, A. / Pardo, J.M. / Tejedor, S. / Farinas, S.C. / Lucas, R. / Figueroa, S. / Jantus-Lewintre, E. / Camps, C. / Farras, R. et al. | 2014
- 116
-
361 Nanoformulations of the PARP inhibitors olaparib and BMN 673 for cancer nanotherapySridhar, S. / Tangutoori, S. / Baldwin, P. et al. | 2014
- 116
-
359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinibWilliams, J.A. / Martini, J.F. / Escudier, B. / Rini, B.I. / Motzer, R.J. / Tarazi, J. / Li, S. / English, P.A. et al. | 2014
- 116
-
360 Tumor suppressive microRNA-192 as a prognostic factor for recurrence of surgically resected non-small cell lung cancerHong, J.H. / Roh, K.S. / Jeon, E.K. / Kang, J.H. / Suh, S.S. / Lee, S.C. et al. | 2014
- 117
-
363 Cytosolic p21 is a pharmacodynamic marker of CHEK1 and IKK inhibition in ovarian cancer cellsKim, M. / Min, D.J. / Wright, G. / Annunziata, C. et al. | 2014
- 117
-
362 Phenotypic plasticity in epithelial progenitors and mesenchymal carcinoma is regulated by Axl signalingEngelsen, A. / Wnup-Lipinska, K. / Tiron, C. / Pelissier, F. / Jokela, T. / Haaland, G. / Gausdal, G. / Sandal, T. / Frink, R. et al. | 2014
- 117
-
364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAFNRAS-mutant melanomaMiddleton, M. / Rasco, D.W. / Olszanski, A.J. / Corrie, P. / Lorigan, P. / Plummer, R. / Larkin, J. / Pavlick, A. / Zhou, X. et al. | 2014
- 118
-
367 Induction of apoptosis and inhibition of angiogenesis by novel fusion protein - AD-O54.9 as a new preclinical strategy in cancer treatmentRozga, P. / Zerek, B. / Pieczykolan, A. / Galazka, M. / Bukato, K. / Pawlak, S. / Szymanik, M. / Jaworski, A. / Teska-Kaminska, M. et al. | 2014
- 118
-
365 Pim-1 kinase: Validated as a therapeutic cancer target for MYC-driven tumoursRenner, O. / Cecilia, Y. / de Miguel, M.C.R. / Peregrina, S. / Garcia-Serelde, B. / Albarran, M.I. / Cebria, A. / Cebrian, D. / Ramos-Lima, F. et al. | 2014
- 118
-
366 Targeting colorectal and pancreatic cancer stem cells with the LGR5 monoclonal antibody BNC101Chu, P. / Shojaei, F. / Smith, K. / Norton, J. / Walsh, C. / Iglesias, J. / Reyes, C. et al. | 2014
- 118
-
368 NP137, the first humanized monoclonal antibody directed against netrin-1, exhibits antitumor activity by inducing dependence receptors-mediated cell deathDelcros, J.G. / Ducarouge, B. / Abes, R. / Goldschneider, D. / Gibert, B. / Blachier, J.G. / Neves, D. / Mehlen, P. / Bernet, A. et al. | 2014
- 119
-
369 Diagnosis and molecular targeting for individualized treatment of patients with pre-neoplastic lesions and locally advanced cervical cancerMoreno-Acosta, P.M.A. / Romero-Rojas, A.R.R.A. / Salgado, A.H.S.A.H. / Mayorga, D.M.D. / Morales, N.M.N. / Acosta, J.A.J. / Gamboa, O.G.O. / Magne, N.M.N. / Molano, M.M.M. et al. | 2014
- 119
-
370 Discovery of the genes that underpin the transition to malignant phenotype of breast tissues in a highly consanguineous regionGupta, I. / Shanmuganathan, S. / Ouhtit, A. et al. | 2014
- 119
-
371 Selective targeting of head and neck cancer cells by perturbing reactive oxygen species homeostasisKwon, M. / Kim, J.W. / Kim, E.H. / Park, J.Y. / Kim, S.Y. / Roh, J.L. et al. | 2014
- 120
-
374 Neuregulin 1 (NRG1) expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor modelsMeetze, K. / Vincent, S. / Tyler, S. / Mazsa, E. / Delpero, A. / Bottega, S. / McIntosh, D. / Gyuris, J. / Weng, Z. et al. | 2014
- 120
-
372 Specific inhibition of hTERT expression by targeting common promoter mutations which cause quadruplex DNA instabilityMiller, D. / Sokolova, A. / Thomas, S. / Rezzoug, F. / Chaires, J. / Dean, W. / Buscaglia, R. / Trent, J. et al. | 2014
- 120
-
375 MER as a novel therapeutic target in colorectal cancerWong, K. / Tan, A.C. / Pitts, T. / Klauck, P. / Earp, S. / Frye, S. / Wang, X. / Graham, D.K. / Eckhardt, S.G. et al. | 2014
- 120
-
373 AKT2 gene amplification is a marker for sensitivity to allosteric but not ATP-competitive AKT inhibitorsAbe, T. / Ichikawa, K. / Fujita, R. / Okada, M. / Tanaka, K. / Ohkubo, M. / Yonekura, K. / Shimomura, T. / Utsugi, T. et al. | 2014
- 121
-
378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignanciesde Weger, V. / Lolkema, M.P. / Dickson, M. / Le Cesne, A. / Wagner, A. / Merqui-Roelvink, M. / Varga, A. / Tap, W. / Schwartz, G. et al. | 2014
- 121
-
376 Tumor-targeting Salmonella typhimurium A1-R enhances gemcitabine-bevacizumab efficacy on a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse modelHiroshima, Y. / Zhao, M. / Katz, M.H.G. / Fleming, J.B. / Sato, S. / Murakami, T. / Yamamoto, M. / Uehara, F. / Miwa, S. et al. | 2014
- 121
-
Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanomaDel Vecchio, M. / Di Guardo, L. / Ascierto, P.A. / Grimaldi, A.M. / Sileni, V.C. / Pigozzo, J. / Ferraresi, V. / Nuzzo, C. / Rinaldi, G. / Testori, A. et al. | 2014
- 121
-
377 Plucked hair as a platform for monitoring pharmacodynamic and mechanistic consequences of clinical exposure to the Wntbeta-catenin inhibitor PRI-724Miele, G. / Reed, B. / Harrison, E. / Mefo, T. / Read, J. / Senba, T. / Odagami, T. et al. | 2014
- 122
-
379 Identification and rational in silico-based targeting of a novel mediator of metastatic breast cancerClarkson, R. / Soukupova, J. / Wakefield, A. / Turnham, D. / Yang, W. / Bordoni, C. / Westwell, A. / Brancale, A. et al. | 2014
- 122
-
381 Efficacy of specific FGFR inhibitors against gatekeeper resistance mutations and shared mechanism of cell death in FGFR2-dependent endometrial cancer cell linesPacker, L. / Byron, S. / Stehbens, S. / Loch, D. / Dehkhoda, F. / Stephenson, S. / Pollock, P. et al. | 2014
- 122
-
382 Phase Ib study of oral dual-PI3KmTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6 + bevacizumab in patients with advanced solid tumors and colorectal cancerRosen, L. / Goldman, J. / Hubbard, J.M. / Roos, M. / Capdevila, J. / Maynes, J. / Lin, W. / O'Keeffe, B. / Lackner, M. et al. | 2014
- 122
-
380 Induction of apoptosis with a novel dual cIAP1XIAP antagonist in models of melanomaWard, G. / Chessari, G. / Johnson, C.N. / Lewis, J. / Rich, S. / Thompson, N. et al. | 2014
- 123
-
383 Identification of potent and selective tankyrase 12 inhibitors with activity in a subset of APC mutant colorectal cancerGuichard, S.M. / Zhang, Y. / Ferguson, D. / Mazzola, A. / Wang, H. / Bao, L. / Grosskurth, S. / Johannes, J. / Wagoner, M. et al. | 2014
- 123
-
384 REDX04988, a novel dual B-RAFC-RAF inhibitor and a potential therapeutic for BRAF-mutant colorectal cancerRainard, J. / Testar, R. / Poonawala, R. / Mason, H. / Smith, P. / Brooke, H. / Huart, V. / Frith, S. / Ahmet, J. et al. | 2014
- 123
-
385 Noninvasive monitoring of acquired EGFR-T790M mutation and discovery of its heterogeneity in patients with advanced NSCLC treated with EGFR-TKIYe, X. / Zheng, D. / Zhang, M.Z. / Sun, Y. / Wang, J.Y. / Ni, J. / Zhang, H.P. / Zhang, L. / Luo, J. et al. | 2014
- 124
-
387 Combination of the ERK inhibitor GDC-0994 with the MEK inhibitor cobimetinib significantly enhances anti-tumor activity in KRAS and BRAF mutant tumor modelsMerchant, M. / Chan, J. / Orr, C. / Cheng, J. / Wang, X. / Hunsaker, T. / Wagle, M.C. / Huang, S.A. / Tremayne, J. et al. | 2014
- 124
-
386 PI3K and MEK inhibitor combination toxicities and relative dose intensity: Vall d'Hebron experienceAzaro, A. / Marino, D. / Garrido-Castro, A. / Cruz, C. / Alsina, M. / Perez, J. / Dienstmann, R. / Argiles, G. / Hierro, C. et al. | 2014
- 124
-
388 An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumorsCardnell, R.J. / Behrens, C. / Diao, L. / Fan, Y. / Tang, X. / Minna, J.D. / Mills, G.B. / Heymach, J.V. / Wistuba, I.I. et al. | 2014
- 125
-
389 A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumorsPapadopoulos, K. / Tolcher, A. / Kittaneh, M. / Patniak, A. / Rasco, D. / Chambers, G. / Newth, G. / Savage, R. / Hall, T. et al. | 2014
- 125
-
392 Using modelling & simulation to integrate mouse PK-PD-efficacy with preliminary human PK data to inform the Phase II doses and schedule for the experimental c-Met inhibitor AZD6094 (Volitinib)Jones, R. / Cheung, A. / Coleman, T. / Ballard, P. / D'Cruz, C. / Schuller, A. / Frigault, M. / Gu, Y. / Sai, Y. et al. | 2014
- 125
-
390 Inhibitors of EZH2 act synergistically with type 1 interferon to induce a potent interferon-stimulated gene response, triggering apoptosis in diffuse large B-cell lymphomaBradley, B. / Zhao, F. / Yuan, C.C. / Balasubramanian, S. / Iyer, P. / Hatton, C. / Bryant, B. / Normant, E. / Trojer, P. et al. | 2014
- 125
-
391 LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancersWinski, S. / Baer, B. / Hartley, D. / Rhodes, S. / Wallace, R. / Smith, S. / Nanda, N. / Kunkle, L. / Lee, P. et al. | 2014
- 126
-
393 Small modification of ceritinib enhances the activity against ALKPark, C.H. / Kang, C.H. / Jung, H.J. / Kim, H.R. / Lee, C.O. / Lee, H.K. / Choi, S.U. et al. | 2014
- 126
-
394 Sensitivity of acute myeloid leukemia cells to a urokinase-activated anthrax lethal toxin (PrAgU2lf) is dependent on uPAR expression and phospho-MEK12 levelsBekdash, A. / Liu, S.H. / Leppla, S.H. / Frankel, A.E. / Abi-Habib, R. et al. | 2014
- 126
-
395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)Choueiri, T.K. / Escudier, B. / Pal, S.K. / Jonasch, E. / Heng, D. / Powles, T. / Arkenau, H.T. / Clark, E. / D'Cruz, C. et al. | 2014
- 127
-
398 TAS-119 a selective inhibitor of Aurora A kinase, potentiates taxane therapy in breast and lung cancer modelsNakatsuru, Y. / Hashimoto, A. / Sootome, H. / Ito, K. / Sakuragi, M. / Miura, A. / Oda, N. / Hirai, H. / Utsugi, T. et al. | 2014
- 127
-
397 Characterization of molecular targets of therapy in Non-Small Cell Lung Cancer (NSCLC) utilizing a liquid biopsyGreene, S. / Lu, D. / Krupa, R. / Harvey, M. / Louw, J. / Jendrisak, A. / Bales, N. / Marrinucci, D. / Gray, J. et al. | 2014
- 127
-
396 Gastrointestinal stromal tumor associated with neurofibromatosis type ITakahashi, T. / Nishida, T. / Nakatsuka, R. / Kaneda, M. / Hirota, S. / Miyazaki, Y. / Kurokawa, Y. / Yamasaki, M. / Miyata, H. et al. | 2014
- 128
-
Primary cardiac sarcomas: A retrospective study of the French Sarcoma GroupIsambert, N. / Ray-Coquard, I. / Italiano, A. / Rios, M. / Kerbrat, P. / Gauthier, M. / Blouet, A. / Chaigneau, L. / Duffaud, F. / Piperno-Neumann, S. et al. | 2014
- 128
-
399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt-beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept studyDey, N. / De, P. / Leyland-Jones, B. et al. | 2014
- 128
-
402 Characterization of the oncogenic properties of mutant isocitrate dehydrogenase 1 (IDH1R132H) in human primary cellsBarradas, M. / Diezma, L. / Perez-Ferreiro, C.M. / Cerezo, A. / Lospitao, E. / Peregrina, S. / Jimenez, S. / Brooks, N.A. / Torres, R. et al. | 2014
- 128
-
400 Optimization of novel pyrido[2,3-b]pyrazine based small molecule fibroblast growth factor receptor 1, 2, 3 & 4 (FGFR) inhibitors into a potential clinical candidateAngibaud, P. / Querolle, O. / Berdini, V. / Saxty, G. / Cleasby, A. / Colombel, H. / Csoka, I. / Esser, N. / Gilissen, R. et al. | 2014
- 128
-
401 TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signalingKato, M. / Miyadera, K. / Ito, K. / Aoyagi, Y. / Hashimoto, A. / Yonekura, K. / Iwasawa, Y. / Utsugi, T. et al. | 2014
- 129
-
405 Aurora kinases A and B are required for KRAS-induced lung cell oncogenicitySantos, E.O.O.d. / Aoki, M.N. / Levantini, E. / Basseres, D.S. et al. | 2014
- 129
-
404 Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lungCavazzoni, A. / Bonelli, M. / Saccani, F. / La Monica, S. / Galetti, M. / Caffarra, C. / Cretella, D. / Fumarola, C. / Alfieri, R. et al. | 2014
- 129
-
403 A novel dielectrophoretic microwell array system for detection and single cell analysis of circulating tumor cells from breast cancer patientsSawada, T. / Morimoto, A. / Mogami, T. / Iijima, K. / Akiyama, Y. / Katayama, K. / Futami, T. / Yunokawa, M. / Tamura, K. et al. | 2014
- 130
-
409 Transcription factor activating protein 2 beta (TFAP2B) mediates neuronal differentiation in neuroblastomaIkram, F. / Ackermann, S. / Roels, F. / Volland, R. / Hero, B. / Hertwig, F. / Kocak, H. / Dreidax, D. / Henrich, K.O. et al. | 2014
- 130
-
406 Aflibercept (Zaltrap) directly attenuates the migration and invasion of colorectal cancer cellsBouygues, A. / Mesange, P. / Ayadi, M. / Poindessous, V. / Chiron, M. / Dochy, E. / Andre, T. / de Gramont, A. / Larsen, A.K. et al. | 2014
- 130
-
407 Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379Alvarado, D. / Lee, S. / Greenlee, E. / Ligon, G.F. / Lillquist, J.S. / Natoli, E.J. / Amick, J. / Hadari, Y. / Schlessinger, J. et al. | 2014
- 130
-
408 A potent and selective small molecule inhibitor of MCL-1 sensitizes DLBCL cell lines to the BCL-2 selective inhibitor ABT-199Phillips, D.C. / Xiao, Y. / Lam, L. / Litinovic, E. / Roberts-Rapp, L. / Souers, A.J. / Leverson, J.D. et al. | 2014
- 131
-
412 The Pediatric Preclinical Testing Program (PPTP): Analysis of the first 10 years in vivo testingHoughton, P. / Lock, R. / Carol, H. / Gorlick, R. / Kolb, A. / Maris, J. / Keir, S. / Wu, J. / Kang, M. et al. | 2014
- 131
-
410 Pediatric Preclinical Testing Program (PPTP) Evaluation of the p53-MDM2 Antagonist MK-8242Smith, M. / Kang, M. / Reynolds, P. / Lock, R. / Carol, H. / Gorlick, R. / Kolb, A. / Maris, J. / Keir, S. et al. | 2014
- 131
-
411 Druggability of p16 deleted pediatric leukemia: The novel cell line POETIC3 identifies potential agents and drug combinations for mechanism based targeted therapeuticsReimer, J. / Kovulchuk, A. / Ruan, Y. / Shah, R. / Jayanthan, A. / Perinpanayagam, M. / Truong, T. / Auer-Grzesiak, I. / Luider, J. et al. | 2014
- 132
-
413 Next-generation sequencing identifies the mechanism of tumourigenesis caused by loss of SMARCB1 in malignant rhabdoid tumoursFinetti, M.A. / Selby, M. / del Carpio Pons, A. / Wood, J. / Skalkoyannis, B. / Smith, A. / Crosier, S. / Bailey, S. / Clifford, S. et al. | 2014
- 132
-
414 Genomic profiling using a clinical next generation sequencing (NGS) assay reveals genomic alterations to guide targeted therapy in advanced neuroblastoma patientsAli, S. / Sanford, E.M. / Hawryluk, M.J. / Chmielecki, J. / Wang, K. / Palmer, G.A. / Palma, N.A. / Morosini, D. / Erlich, R. et al. | 2014
- 132
-
415 Comprehensive next generation sequencing of solid tumors from 669 adolescents and young adults reveals a distinct spectrum of targetable genomic alterationsMorosini, D. / Wang, K. / Wagner, K. / Gershenhorn, B. / Yelensky, R. / Lipson, D. / Chmielecki, J. / Ali, S.M. / Ross, J.S. et al. | 2014
- 133
-
417 Evaluating the activity of the p53-MDM2 inhibitor NDD0005 in Ewing sarcomaPecqueur, J. / Vormoor, B. / Zhao, Y. / Newell, H. et al. | 2014
- 133
-
418 Population pharmacokinetics of intravenous bolus 5-fluorouracil in a phase I trial for children and young adults with recurrent ependymomaTurner, D.C. / Haddock, K.M. / Jacus, M.O. / Harstead, K.E. / Throm, S.L. / Daryani, V.M. / Stewart, C.F. / Wright, K.D. et al. | 2014
- 133
-
416 Results of phase I study of bolus 5-fluorouracil in children and young adults with recurrent ependymomaWright, K.D. / Turner, D.C. / Haddock, K.M. / Jacus, M.O. / Harstead, K.E. / Throm, S.L. / Daryani, V.M. / Robinson, G.W. / Armstrong, G.T. et al. | 2014
- 134
-
419 Targeted inhibition of casein kinase II (CK2) produces a strong therapeutic effect in pediatric leukemiaDovat, S. / Song, C. / Gowda, C. / Payne, K.J. et al. | 2014
- 134
-
420 Analysis of genomic alterations in Ewing sarcoma (German cohort) reveals cooperating mutations and novel therapy targetsRichter, G.H.S. / Agelopoulos, K. / Schmidt, E. / von Heyking, K. / Moser, B. / Klein, H.U. / Kontny, U. / Dugas, M. / Poos, K. et al. | 2014
- 135
-
421 Molecular profiling for factors predicting sensitivity or resistance to therapy in relapsed child cancerSaletta, F. / Wadham, C. / Byrne, J. / Ziegler, D. / McCowage, G. / Haber, M. / Marshall, G. / Norris, M. et al. | 2014
- 135
-
423 RNA helicase A is essential for 1p36 gene KIF1B@b tumor suppression in neuroblastomasChen, Z.X. / Wallis, K. / Fell, S.M. / Sobrado, V.R. / Hemmer, M.C. / Ramskold, D. / Choo, Z. / Hellman, U. / Sandberg, R. et al. | 2014
- 135
-
422 CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in pre-clinical models of neuroblastomaHaber, M. / Murray, J. / Gamble, L. / Carnegie-Clark, A. / Webber, H. / Ruhle, M. / Carter, D. / Oberthur, A. / Fischer, M. et al. | 2014
- 136
-
425 Evaluation of drug reactions to anti-neoplastic agents in Phase I clinical trialsBupathi, M. / Hajjar, J. / Hess, K. / Bean, S. / Karp, D. / Meric-Bernstam, F. / Naing, A. et al. | 2014
- 136
-
424 Nonclinical safety assessment of a humanized anti-OX40 agonist antibody, MOXR0916Prell, R. / Halpern, W. / Beyer, J. / Tarrant, J. / Sukumaran, S. / Huseni, M. / Kaiser, R. / Wilkins, D. / Karanth, S. et al. | 2014
- 136
-
426 Serum levels of CCL22 and CCL25 might predict skin rash induction the commonest adverse event by bendamustine in the treatment of malignant lymphomaTerni, Y. / Kuniyoshi, R. / Mishima, Y. / Hatake, K. et al. | 2014
- 136
-
427 Hematotoxicity potential of new drug candidates measured in hematopoietic progenitors in bone marrow samplesBallesteros, J. / Primo, D. / Hernandez, P. / Robles, A. / Espinosa, A.B. / Arroyo, E. / Garcia-Navas, V. / Sanchez-Fenoy, J. / Jimenez, M. et al. | 2014
- 137
-
Identification of brain tumour initiating cells using the stem cell marker aldehyde dehydrogenaseChoi, S.A. / Lee, J.Y. / Phi, J.H. / Wang, K.-C. / Park, C.-K. / Park, S.-H. / Kim, S.-K. et al. | 2014
- 141
-
428 Clinical acquired resistance to combined RAFEGFR or RAFMEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterationsCorcoran, R. / Coffee, E.M. / van Allen, E. / Ahronian, L.G. / Wagle, N. / Kwak, E.L. / Faris, J.E. / Iafrate, A.J. / Garraway, L.A. et al. | 2014
- 141
-
430 Design and structure-activity relationships of highly potent and bioavailable imidazolinone FASN KR domain inhibitorsBignan, G. / Alexander, R. / Bischoff, J. / Connolly, P. / Cummings, M. / de Breucker, S. / Esser, N. / Fraiponts, E. / Gilissen, R. et al. | 2014
- 141
-
429 Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapyMyers, S. / Martin, N. / Bawn, R. / Blackburn, T. / Barrett, L. / Reuillon, T. / Golding, B. / Griffin, R. / Hammonds, T. et al. | 2014
- 142
-
431 Real-time pharmacokinetic (PK) results from an ongoing randomized, parallel-dose phase 1 study of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancersLokiec, F. / Bonneterre, J. / Italiano, A. / Varga, A. / Campone, M. / LeSimple, T. / Leary, A. / Dieras, V. / Rezai, K. et al. | 2014
- 142
-
432 ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong anti-tumor activity in FGFR- and VEGFR-dependent cancer modelsHolmstrom, T. / Moilanen, A. / Linnanen, T. / Wohlfahrt, G. / Karlsson, S. / Oksala, R. / Korjamo, T. / Bjorkman, M. / Samajadar, S. et al. | 2014
- 142
-
433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kinaseSootome, H. / Fujita, N. / Miura, A. / Suzuki, T. / Fukushima, H. / Mizuarai, S. / Hirai, H. / Utsugi, T. et al. | 2014
- 143
-
435 A pan-cancer tumor-derived epithelial-to-mesenchymal transition (EMT) signature determines patterns of drug sensitivity and enrichment in immune target expression following EMTMak, M.P. / Tong, P. / Diao, L. / Ng, P.K.S. / Fan, Y. / Cardnell, R.J. / Gibbons, D.L. / William, W.N. / Heymach, J.V. et al. | 2014
- 143
-
434 Bipolar androgen therapy for men with castration sensitive and castration resistant prostate cancer: Reversing resistance and maintaining sensitivity to androgen ablative therapiesDenmeade, S.R. / Antonarakis, E.S. / Eisenberger, M.A. / Carducci, M.A. / Wang, H. / Paller, C.J. / Isaacs, J.T. / Schweizer, M.T. et al. | 2014
- 143
-
436 Monitoring activity of RXDX-101 in Phase 12 patients using a pharmacodynamic assay for TrkA activationMurphy, D. / Ely, H. / Patel, R. / Wei, G. / Diliberto, A. / Shoemaker, R. / Christiansen, J. et al. | 2014
- 144
-
438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigenHarms, B.D. / Lugovskoy, A. / Abu-Yousif, A. / Fulgham, A. / Geddie, M. / Su, S.V. / Kohli, N. / Johnson, B. / Masson, K. et al. | 2014
- 144
-
440 Phenotypic alteration in a highly metastatic variant of the MDA-MB-231 cell line: role of Annexin A1Tu, Y. / Fietz, E. / Cameron, J. / Stewart, A. et al. | 2014
- 144
-
439 PI3KmTOR inhibitor VS-5584 targets cancer stem cells and prevents tumor regrowth after chemotherapy in preclinical models of small cell lung cancerKolev, V. / Padval, M. / Wright, Q. / Ricono, J. / Weaver, D. / Pachter, J. / Xu, Q. et al. | 2014
- 144
-
437 PIM kinase inhibitor AZD1208 sensitises SCLC to BH3 mimetic AZD4320Sloane, R. / Bola, B. / Lancashire, M. / Hodgkinson, C. / Morrow, C. / Simpson, K. / Dive, C. et al. | 2014
- 145
-
441 The role of methylation in metastasis of oral squamous cell carcinoma: understanding the OSCC methylomeClausen, M. / Melchers, L.J. / de Meyer, T. / Denil, S. / Criekinge, W. / Wisman, G.B. / Roodenburg, J.L.N. / Schuuring, E. et al. | 2014
- 145
-
443 Notch3-targeted antibody drug conjugates have superior preclinical efficacy to Notch signaling inhibitorsGeles, K.G. / Gao, Y. / Sridharan, L. / Giannakou, A. / Yamin, T.T. / Golas, J. / Charati, M. / Lucas, J. / Wang, K. et al. | 2014
- 145
-
442 Targeting urokinase plasminogen activator for radioimmunotherapy using an antagonistic internalizing human antibodyLeBeau, A. / VanBrocklin, H.F. et al. | 2014
- 146
-
445 MEK inhibition enhances gemcitabine efficacy by increasing MDM2-mediated ubiquitination and degradation of RRM1Vena, F. / Li Causi, E. / Hagemann, T. / Hartley, J.A. / Goodstal, S. / Hochhauser, D. et al. | 2014
- 146
-
444 Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and platinum-refractory epithelial ovarian cancer (EOC). Preliminary results of a Phase I dose-escalation studyLe Tourneau, C. / Ray-Coquard, I. / Isambert, N. / Gomez-Roca, C.A. / Cassier, P. / Sablin, M.P. / Ruits, E. / Gavillet, B. / Zanna, C. et al. | 2014
- 146
-
446 The cancer stem cell inhibitors VS-6063 (defactinib) and VS-5584 exhibit synergistic anticancer activity in preclinical models of mesotheliomaXu, Q. / Tam, W.F. / Vidal, C.M. / Kolev, V.N. / Kadariya, Y. / Menges, C.W. / Testa, J.R. / Pachter, J.A. et al. | 2014
- 147
-
447 Novel, quantitative in vivo shRNA screening approach identifies new molecular targets to block cancer metastasisWilletts, L. / Paproski, R. et al. | 2014
- 147
-
450 Precise gene editing of mutant NRAS using CRISPR to determine sensitivity to trametinibHose, C. / Fer, N.D. / Burkett, M. / Connelly, J. / Harris, E. / Lih, J. / Williams, M. / Evans, D. / Silvers, T. et al. | 2014
- 147
-
448 Exposure to EGFR inhibitors influences release of extracellular vesicles by tumor cellsvan der Meel, R. / van Dommelen, S.M. / de Corte, P. / Coimbra, M. / van Solinge, W.W. / Vader, P. / Schiffelers, R.M. et al. | 2014
- 147
-
449 Cytokine induces MIR-424 expression and modulates SOCS2STAT5 signaling pathway in oral cancerShiah, S.G. / Peng, H.Y. / Jin, S.L.C. / Chang, J.Y. / Kuo, C.C. et al. | 2014
- 148
-
452 eIF2alpha phosphorylation determines the adaptation of tuberous sclerosis complex mutant cells to stress and their response to anti-tumor therapiesKoromilas, A. / Tenkerian, C. / Krishnamoorthy, J. / Kamindla, R. / Kazimierczak, U. / Wang, S. et al. | 2014
- 148
-
453 Plasma metabolomic signature of novel signal transduction inhibitors from preclinical identification to clinical validationAng, J.E. / Pandher, R. / Asad, Y. / Skene, D.J. / Workman, P. / Eccles, S. / de Bono, J. / Kaye, S. / Banerji, U. et al. | 2014
- 148
-
451 Correlative and updated clinical endpoint analysis of a multicenter phase II trial of selumetinib (AZD6244) plus erlotinib in chemotherapy-refractory advanced pancreatic adenocarcinoma (PDAC)Ko, A.H. / Tempero, A.H. / Bekaii-Saab, T.B. / Kuhn, P. / Courtin, R. / Ziyeh, S. / Tahiri, S. / Kelley, R.K. / Dito, E. et al. | 2014
- 149
-
454 Monitoring therapy response and resistance mutations in circulating RNA and DNA of plasma from patients with malignant melanomaEnderle, D. / Brinkmann, K. / Koestler, T. / Bentink, S. / Flaherty, K.T. / Skog, J. / Noerholm, M. et al. | 2014
- 149
-
455 Role of MDM2 as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)Briest, F. / Grass, I. / Christen, F. / Lewens, F. / Freitag, H. / Kaemmerer, D. / Saenger, J. / Hummel, M. / Siegmund, B. et al. | 2014
- 149
-
456 SF3B1 mutations induce disease relevant aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibitionBuonamici, S. / Lim, K. / Feala, J. / Darman, R. / Myint, K. / Park, E. / Aird, D. / Chan, B. / Fekkes, P. et al. | 2014
- 150
-
Quantitative and qualitative analysis of study-related patient information sheets in randomised neuro-oncology phase III-trialsReinert, C. / Kremmler, L. / Burock, S. / Bogdahn, U. / Wick, W. / Gleiter, C.H. / Koller, M. / Hau, P. et al. | 2014
- 150
-
458 Combinational genome and proteome survey of therapeutic targets of hepatocellular carcinomaYamada, T. et al. | 2014
- 150
-
459 Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigationMortensen, D.S. / Fultz, K.E. / Xu, W. / Tsuji, T. / Hickman, M. / Abbasian, M. / Khambatta, G. / Cathers, B. / Worland, P. et al. | 2014
- 150
-
457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamideDavies, B.R. / Thomason, A. / Ellston, R. / Campbell, H. / D'Cruz, C. / Mazzola, A.M. / Zhou, T. / Schmidt, J. / Jo, M. et al. | 2014
- 150
-
460 Molecular biomarkers of inflammatory signature in melanomaEkmekcioglu, S. / Shin-Sim, M. / Tanese, K. / Prieto, V.G. / Hoon, D.S. / Grimm, E.A. et al. | 2014
- 151
-
463 PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugsPrahallad, A. et al. | 2014
- 151
-
461 A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF mutated advanced malignanciesHaraldsdottir, S. / Janku, F. / Timmers, C. / Geyer, S. / Schaaf, L.J. / Sexton, J. / Thurmond, J. / Velez-Bravo, V. / Stepanek, V.M. et al. | 2014
- 151
-
464 Influence of warm and cold ischemia on molecular patterns in clinical biospecimenUnger, F.T. / Lange, N. / Uhlig, P.C. / Juhl, H. / David, K.A. et al. | 2014
- 151
-
462 Clinical sequencing of cancer in real-time by digital sequencing of cell-free DNA for tailoring targeted therapy in refractory cancer patientsTalasaz, A. / Mortimer, S. / Schiller, B.J. / Mei, G. / Huang, S. / Hoon, D.S.B. / Eltoukhy, H. et al. | 2014
- 152
-
467 Two in one - Delivery of apoptotic signal into cancer cells by new class of TRAIL derived, fusion proteinPawlak, S.D. / Zerek, B.M. / Rozga, P.K. / Bukato, K. / Szymanik, M. / Teska-Kaminska, M. / Pieczykolan, A. / Jaworski, A. / Galazka, M. et al. | 2014
- 152
-
465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)Kapoun, A. / O'Reilly, E. / Cohn, A. / Bendell, J.C. / Smith, L. / Strickler, J.H. / Gluck, W. / Liu, Y.W. / Wallace, B. et al. | 2014
- 152
-
466 IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapiesQuetglas, I.M. / Pinyol, R. / Dauch, D. / Portela, A. / Villanueva, A. / Peix, J. / Higuera, M. / Moeini, A. / Zucman-Rossi, J. et al. | 2014
- 153
-
470 Transcriptional regulation of cancer stem cells marker CD133 by p53Park, E.K. / Bang, S.Y. / Yi, S.A. / Han, J.W. et al. | 2014